Drugs, Narcotics & the Epstein Network

Operation Chain Reaction, multiagency intelligence profile

Documented: An OCDETF/DEA multiagency profile identifies Epstein as Target 4 within a 15-target investigation opened December 17, 2010. The profile is marked Pending Judicial as of 2015 and describes an intelligence lead concerning suspected illicit wire transfers tied to drug and/or prostitution activities in the USVI and New York.

Limits: The product is an investigative lead. No charging recommendation, final disposition, drug identification, or proof of the suspected transactions is established by the published memorandum.

Verify: Obtain unredacted profile, underlying DEA case history, evidence attachments, charging memoranda, final closure notices and case-agent explanations.

Seven Epstein-related SAR references require overlap controls

Documented: The DEA profile summarizes seven Epstein-subject suspicious-activity reports in 2013–2015, roughly $5.67 million, as well as currency-transaction reporting. Its own analyst note says some financial reports name several investigation targets.

Limits: Amounts are report-level indicators, not proof of independent transfers or illegal drug proceeds. Avoid adding multi-target SAR totals across subjects. Exact cents and underlying source filings were not independently reconciled.

Verify: Request or lawfully obtain each underlying SAR identifier, reporting date, institution, transaction roster, unique instruments and beneficiary fields; de-duplicate by instrument.

Two separate incapacitation accounts in the Brunel inquiry

Documented: A French mutual-legal-assistance request records one account of feeling drugged before sexual assault and a distinct account of losing consciousness after consuming a cocktail prepared by Jean-Luc Brunel and awakening with bruises.

Limits: The documents establish reported experiences and their inclusion in the French investigation. No laboratory-confirmed drug or court finding on the precise mechanism of incapacitation is established in this source.

Verify: Find the respective interview procès-verbaux, any toxicology or clinical records, corroborating witness testimony and later judicial disposition; keep survivor identity protected.

FBI crisis intake separately reports drugging and loss of consciousness

Documented: An FBI National Threat Operations Center intake dated October 8, 2019 records a reporting person’s account of being drugged and moving in and out of consciousness before rape in 1984.

Limits: This is a crisis-intake account, not an FBI corroboration determination, forensic assessment, or proof of a specific substance. The original publicly accessible version contains identifying fields; these are deliberately excluded.

Verify: Determine whether the intake led to a follow-up interview, supporting evidence, investigation disposition and independent corroboration.

Separate the 27 LSJ digital devices from complete island inventory

Documented: A June 2020 sworn warrant affidavit identifies 27 electronic devices seized at Little Saint James on August 12, 2019, 33 devices recovered from the Manhattan residence and two from Epstein at arrest. It states that the devices were transported to FBI offices in the Southern District of New York.

Limits: These are defined electronic exhibits, not an island-wide substances inventory or toxicology assessment. Counts do not establish seized chemicals or lawful procurement.

Verify: Reconcile each original seizure and custody identifier with the island-wide inventory, forensic image reports, laboratory submissions and any drug-related search returns.

Original island item spreadsheet named but not produced in reviewed email

Documented: An August 23, 2019 FBI/NYPD task-force email refers to attachments VI_SW_item_list.xlsx and C2O_LSJ_12AUG2019_-_PDF.pdf, described as a complete item list and tactical-plan aid.

Limits: Neither attachment content was independently recovered during this sweep. Consequently there is no justified claim of a positive or negative controlled-substance seizure finding.

Verify: Locate original spreadsheet bytes and attachment metadata; compare against numbered physical exhibits, evidence-custody records and later forensic returns.

Distinct 2019 SAR cohorts expose reporting delays

Documented: The August 2026 Senate report describes JPMorgan SAR filings on August 13, 2019 (469 wires, about $201 million) and September 26, 2019 (an additional 4,725 wires, about $1.08 billion), and identifies 134 JPMC accounts related to Epstein or associated parties during 1998–2013.

Limits: The committee findings concern trafficking and AML deficiencies; they do not identify these wires as narcotics proceeds. Do not summate this reporting with the 2015 DEA totals absent SAR-by-SAR reconciliation.

Verify: Match unique transaction identifiers, bank statements, SAR report identifiers and counterparty records with DEA profile reporting years and institutions.

Cash pattern and structuring inquiries distinguished

Documented: NYDFS documents 97 $7,500 cash withdrawals by Attorney-1 during 2013–2017, inquiries about triggering cash alerts in May 2014 and July 2017, and a 2017 instance of splitting a planned withdrawal across two days after asking about the $10,000 reporting threshold. The order reports over $800,000 total attorney withdrawals on Epstein’s behalf.

Limits: The order describes cash-structuring concerns and records the attorney’s denial of intent. It also says required CTRs were filed. Neither narcotics use of the cash nor criminal guilt is established.

Verify: Reconcile withdrawal dates, CTR filings, the 2017 internal AML escalation, source accounts, destinations and plausible overlap with pre-2015 DEA references.

September 2026 demand for undisclosed banker FD-302

Documented: The Senate committee reported learning that FBI agents interviewed a banker tied to Epstein and requested relevant FD-302 interview reports from DOJ/FBI, including employees at JPMorgan, Deutsche Bank and Bank of America.

Limits: The banker interview report and its contents were not made available in the cited letter. It is improper to infer that it discussed drugs or confirmed financial crimes.

Verify: Locate responsive FBI FD-302 releases, response letters or docket exhibit copies, and compare testimony to bank compliance and 2015 DEA intelligence chronology.

Operation Trip Knot is a distinct case from Chain Reaction

Documented: An FBI import form names Operation Trip Knot and PA-CAE-0525 under an OCDETF Eurasian-organizations heading. On March 16, 2026 Senator Sheldon Whitehouse requested its disposition, results and disclosure of relevant documents.

Limits: The released import form does not itself prove Epstein was a target or participant; the claim that his name surfaced repeatedly is attributed to reporting and is not corroborated by a subject designation on the form. OCR of the FBI case number is uncertain.

Verify: Obtain full operation opening and closing documents, DOJ responsive correspondence, referenced import attachments and corroborated case identifiers.

Bell 430 registration must not be merged with Sikorsky S-76

Documented: An FBI-derived aircraft ownership chronology tracks Bell 430 serial 49078 as N901RL, later N331JE, held via Hyperion-related entities. Another FBI aircraft-summary email places N331JE and serial 49078 beneath an entry for the separate Sikorsky N722JE, making that particular summary inconsistent with the Bell ownership trail.

Limits: The discrepancy may be an email-summary error and requires FAA registration and bill-of-sale cross-checking. Neither the Bell aircraft nor its documented owners have been linked by these records to Southern Air Transport narcotics allegations.

Verify: Obtain FAA airframe histories for both serials and verify each seller/buyer and registration change. Exclude the mistaken Sikorsky cross-assignment in automated network matching.

1987 Customs inquiry and 1991 DEA record concern Southern Air Transport

Documented: The CIA Inspector General reported that a January 1987 Customs inquiry concerned suspected narcotics trafficking by Southern Air Transport crew members and that a February 1991 DEA cable described database reports of alleged cocaine trafficking activity involving the company.

Limits: These were historical intelligence and allegations concerning Southern Air Transport. The reviewed CIA report has not established an ownership, aircraft-serial, personnel, flight or transaction link to Epstein.

Verify: Cross-check individual historical Southern Air aircraft serials, routes and executives against later company files; treat matching generic aviation terms as noise.

Two overlapping pharmaceutical inventories identified

Documented: Independent document search indexing exposes four-page inventories under both EFTA00522943 and EFTA00522035 that include clonazepam/Klonopin 0.5 mg and lorazepam/Ativan 0.5 mg among numerous noncontrolled medicines. The two inventories appear closely related and require page-by-page comparison.

Limits: This sweep did not retrieve a trustworthy original PDF page rendering, chain-of-custody provenance, acquisition records or evidence that listed drugs were administered without consent. Source-collection association cannot establish location or ownership.

Verify: Acquire both original PDFs, perform text/image diff, identify dates and intended user, compare purchase receipts/prescribers, and confirm EFTA00814713 separately.

DDoSecrets original/replacement archive scope

Documented: DDoSecrets publicly lists DOJ datasets 1–12, an original and replacement copy of DataSet 8, DataSet 9 as an approximately 100 GiB 7z, plus separate Epstein emails, FBI releases, SEC documents and CBP material.

Limits: This pass verified the archive catalogue and branch names; it did not download, extract or full-text-search those large datasets. No new drug evidence can be claimed from archive listings alone.

Verify: Compare original/replacement DataSet 8 manifests and hashes, then search lawfully available extracted text using Bates IDs, company aliases and DEA case numbers while excluding confidential victim material.

Three dated Deutsche Bank UCTR identifiers and amounts recovered

Documented: The May 18, 2015 DEA profile identifies UCTR BSA ID 31000036626342 (15 Nov 2013, $20,723 out), 31000038320027 (19 Dec 2013, $21,150 out), and 31000040594074 (31 Jan 2014, $60,775 out). All list Deutsche Bank Trust Company Americas as filing institution. These three reported outflows total $102,648. A redacted person reportedly conducted transactions on Epstein’s behalf.

Limits: The original UCTR filings, payee and ultimate destination are not available in this release. Reporting does not demonstrate that any outflow was for drugs, illicit activity, or was part of the 97 later NYDFS-described withdrawals. Do not decode the redacted intermediary or add this total to unrelated SAR cohorts.

Verify: Request these exact original BSA reports lawfully and retrieve source-account statements, underlying withdrawal instruments and CTR/SAR cross-references. Test any match to the NYDFS 2020 chronology by transaction date and record ID.

Independent 14-page FBI collected-item log for Little Saint James

Documented: A 14-page FBI Collected Item Log dated August 22, 2019 describes seizures from the August 12 Little Saint James search, with categories including computers and tablets, recording or network equipment, handwritten paperwork, photographs and the 2019 boat log. This is an independently identifiable evidence register, separate from the unrecovered VI_SW_item_list.xlsx referenced in EFTA00019668.

Limits: The full original log pages were not rendered and independently audited in this sweep. A source-annotated analysis summarizes them. Neither that summary nor this restricted log can conclusively prove the presence or absence of medicines, laboratory samples or items from other searches. The FBI 31E-NY and 50D-NY identifiers remain separate pending reconciliation.

Verify: Obtain all fourteen original page images and transcribe every item ID and evidence-description field. Compare with the referenced VI_SW_item_list.xlsx, chain-of-custody exhibits, search returns, lab submissions and follow-up inventories.

2010–2015 reporting cutoff excludes older financial records

Documented: The profile expressly states that only 2010–2015 financial reporting was included and that older reporting on the targets was available. The same pages specify Epstein as subject to seven 2013–2015 USARs totaling $5,672,921 and eight 2010–2011 CTRs totaling $233,397. Some financial reports cover multiple targets.

Limits: These dollar figures come from distinct reporting categories and cannot be assumed to be distinct underlying transactions. Older available records are not enumerated in the memo and should not be deemed absent. OCR renders the seven-USAR total incompletely; the page image supports $5,672,921.

Verify: Recover attachments 1, 2 and 3 and the pre-2010 BSA reporting index; deduplicate by institution, report date, BSA identifier and each underlying transaction instrument.

Liquid Funding corporate positions have specific 2001–2007 bounds

Documented: ICIJ’s Appleby/Paradise Papers officer record identifies Jeffrey E. Epstein as a director of Bermuda-incorporated Liquid Funding, Ltd., from November 9, 2001 through March 30, 2007, and chairman from November 9, 2001 through March 19, 2007. Incorporation is listed as October 19, 2000. The officer record associates a U.S. Virgin Islands address with the person.

Limits: The firm’s recorded corporate roles precede the DEA operation opened December 2010. Nothing in this ICIJ record identifies a narcotics transaction, drug-trafficking activity or a relationship to the Operation Chain Reaction financial reporting. Company presence or address reuse does not prove criminal conduct.

Verify: Use Appleby underlying director resolutions and Bermuda annual filings to establish date precision; reconcile corporate accounts only if authenticated bank instruments and a matching 2010–2015 counterparty are recovered.

Court ordered foreign-language EFTA review, relevant to French document retrieval

Documented: Judge Emmet G. Sullivan rejected DOJ’s administrative-inconvenience rationale for declining foreign-language review and ordered review and production to begin, with notice by September 24, 2026. The court separately required in camera production of handwritten FBI notes underlying four listed FD-302 reports. The ruling presents an independent legal pathway for scrutinizing excluded French-language material.

Limits: The order does not identify any additional Brunel witness document, establish that new pharmaceuticals or laboratory results have been released, or prove compliance with the deadline. The four FD-302 numbers in the ruling have not been established as relevant to this drugs investigation.

Verify: Inspect subsequent court filings and DOJ notices for foreign-language review completion and actual released French records. Match only independently identified EFTA documents to the Brunel judicial file.

Chain Reaction cited 2013 FBI case record; serial 251 traces to 2011 Sydney interview

Documented: On internal page 16 of its May 18 2015 Target 4 profile, the DEA expressly cites a July 8, 2013 FBI FD-302 in Miami case 31E-MM-108062. A separately published September 2026 serial crosswalk identifies serial 251 (EFTA00269896) as the March 17, 2011 Sydney survivor interview, logged in a July 8, 2013 registry (EFTA02730486). An independent released-file index identifies EFTA00269896 as a 12-page 2011 interview record. This presents a verifiable interagency information pathway and a 2011 interview / 2013 entry-date question.

Limits: The original DEA citation and the interview document’s identity are directly verifiable, but not every page of the FBI serial registry, import history, and alternative copies has been independently compared in this iteration. A 2011 interview entered in a 2013 registry does not, alone, prove intentional delay, suppression, or concealment. The cited statement concerns the survivor’s account and does not itself establish drug trafficking.

Verify: Obtain original images for EFTA00269896, EFTA00269967, EFTA01249101, EFTA02730486 and EFTA01689026. Compare serial numbers, source phrase and 2011/2013 processing metadata, then seek DEA analyst source-retrieval logs and transmitting FBI correspondence.

SLK Designs: 2014 FinCEN $20,000 reference matches date and beneficiary in 2019 bank exhibit

Documented: The 2015 DEA profile identifies a 2014 USAR in which Jeffrey Epstein and SLK Designs LLC are subjects together, FinCEN BSA ID 31000053179085, and reports a $20,000 transfer. Deutsche Bank’s September 12, 2019 presentation to federal prosecutors, Exhibit N (EFTA01681893), lists Epstein-to-SLK Designs LLC payments via Citibank of $1,500 on Nov. 1, 2013, $1,500 on Dec. 2, 2013, and $20,000 on Apr. 2, 2014. The $20,000 amount and 2014 counterparty align; the presentation adds a candidate transaction date and recipient bank.

Limits: The matching amount/year/beneficiary strongly suggest a single transaction, but the original BSA report and bank payment trace have not been aligned by transaction reference or underlying account number. The $20,000 must not be counted twice in financial totals. A bank exhibit heading referring to alleged co-conspirators is not proof that SLK Designs or its owners committed an offense, and no narcotics purpose appears in these entries.

Verify: Retrieve FinCEN BSA report 31000053179085 and obtain underlying April 2, 2014 wire origin/recipient details; reconcile against the bank exhibit. Check whether the 2013 two $1,500 items represent independent recurring payroll or another documented expense before categorizing.

SLK Designs LLC state formation filing is May 31, 2012; reconcile competing 2009 date

Documented: The reproduced original New York Department of State certificate and articles of organization for SLK Designs LLC give a filed/existence date of May 31, 2012, with filing handled by Darren K. Indyke. A distinct 2026 automated cross-corpus analysis cites a 2013 internal email, EFTA02131473, asserting a Sept. 15, 2009 incorporation date. These are not yet reconciled and may represent different legal dates, an earlier structure, or an error.

Limits: The 2012 filing is a strong original-source record. The 2009 date is derivative pending review of the cited 2013 email and the full legal record; it should never supersede the state’s dated filing without a valid conversion, foreign registration or predecessor explanation. Do not infer sham formation or criminal purpose.

Verify: Obtain original EFTA02131473 and compare exact description; obtain NY DOS company filings, amendments and EIN correspondence. Check whether SLK refers to any predecessor or different entity with similar name before writing a single founding date.

March 18 congressional document-production dispute remains unresolved

Documented: In his original March 18, 2026 letter, Senator Wyden reported a confidential tip that DEA Administrator Terry Cole was ready to send an unredacted Chain Reaction memo to Congress but that Deputy Attorney General Todd Blanche intervened. CBS reported Blanche publicly denied blocking documents and said lawmakers could view an unredacted memo in DOJ’s reading room. This establishes a contested records-production dispute and two separately attributable accounts.

Limits: The Senate letter states an allegation based on a confidential tip; it is not an adjudicated finding that Blanche interfered. The reading-room offer does not by itself establish that Congress received a production or that the underlying DEA attachments were made public. Wyden’s speculation about particular drugs or drug administration is not independently confirmed by the released memo.

Verify: Seek March 2026 DEA-DOJ production correspondence, exact DEA response to committee, room access inventory, records of any subsequent unredacted production and evidence of what was withheld. Distinguish elected-official allegation, departmental denial and independently proved facts.

DEA reportedly invoked anticipated interference with enforcement proceedings in March 2026

Documented: CBS News reported requesting records about the DEA Chain Reaction investigation and receiving a denial referring, at least in part, to records whose disclosure could reasonably be expected to interfere with enforcement proceedings. This is a specified, independently reportable disclosure outcome and provides an exact determination letter to seek.

Limits: The actual DEA response letter, FOIA control number, cited statutory exemptions and scope of responsive records have not been inspected. Quoting an enforcement-interference basis does not independently establish Chain Reaction was still open in 2026, that charges existed, or that the memo contained specific drug types.

Verify: Obtain CBS News’s March 2026 FOIA request and DEA determination; identify FOIA exemption(s), date and appeal history. Request releasable closure metadata/segregable material separately, respecting protected investigations and survivor identities.

Trip Knot is an April 2025 Eurasian-organized-crime vetting record, not a proved Epstein narcotics case

Documented: The FBI import form EFTA00129095 identifies Operation Trip Knot, PA-CAE-0525, OCDETF-Eurasian Organizations. Adjacent EFTA00129096 describes an April 3, 2025 FBI ARMS Reach / enterprise vetting communication for potential proximity to the U.S. president involving a technology investor. Epstein is mentioned in comparisons and relationship descriptions. Chain Reaction instead uses DEA C1-11-0049 and NY-NYS-0829 in a May 2015 profile, establishing a separate case identifier and purpose.

Limits: A vetting/intelligence communication is not a prosecution, sworn proof of its embedded accusations, or proof that Epstein was a target in Trip Knot. Reported behavioral allegations against third parties within EFTA00129096 are outside this Atlas’s verified narcotics scope and are not reproduced. The cover form OCR varies on FBI Sentinel digits; use page images for precise identifier.

Verify: Compare original EFTA00129095 and EFTA00129096 page images for exact Sentinel ID; obtain other case instruments with independently matching case or operation identifiers. Do not join to DEA Chain Reaction or Operation New Blood by the word OCDETF alone.

March 2025 FBI–DOJ review explicitly included an interagency-document approval process

Documented: DOJ published a 41-page PDF on October 9, 2026, disclosing March 2025 FBI–DOJ communications about Epstein-document review. In a March 22 email on Bates page 006, an ODAG correspondent states that there is sign-off for the process for interagency documents in the processing guidance. In a March 23 exchange on Bates page 002, an ODAG correspondent asks reviewers to flag public-figure names not included in the starter list. The release also records instructions to flag encountered videos for a DOJ lawyer.

Limits: These emails concern a March 2025 document-review project and do not identify Chain Reaction, explain its ultimate disposition, or establish that DEA records were deliberately withheld. Significant passages are redacted under FOIA; the referenced processing-guidance document and attachments are not fully available in the release. The review was in 2025, whereas this disclosure occurred in October 2026.

Verify: Request the approved interagency processing guidance, Public Release List 2025.03.23 0810.xlsx, attachment inventory, and document-level scope lists. Compare any disclosed agency origin fields against DEA C1-11-0049, OCDETF NY-NYS-0829, and EFTA00173953 without assuming an overlap.

Bloomberg traced a 2015 informant allegation to ketamine, ecstasy and methamphetamine

Documented: Bloomberg reported, citing five people familiar with the investigation, that an informant told authorities Epstein participated in funding and distribution of ecstasy, ketamine and methamphetamines. It described his inclusion around 2015 within an organized-crime case that had begun earlier. The 2015 69-page official OCDETF profile establishes his Target 4 designation and describes suspected transfers relating to drugs and/or prostitution, but the released profile itself does not enumerate the named substances.

Limits: The drug names derive from reporting by confidential sources, not from a public drug seizure, forensic toxicology, drug invoice or authenticated informant statement. Reporting on investigative suspicion does not prove Epstein financed or distributed any particular drug. Do not connect this allegation automatically to particular survivor accounts.

Verify: Obtain source attribution from DEA investigative file, confidential-source statement redacted appropriately, any substance-specific lab or import records, and a complete agent chronology. Compare timeline against 2010 operation opening, early-2015 referral, and May 18 profile.

June 16, 2023 reported closure date requires the DEA closing instrument

Documented: A research synthesis citing Bloomberg March 2026 reporting gives June 16, 2023 as the official closure date for Operation Chain Reaction. The 2015 OCDETF memorandum confirms that the broader operation began December 17, 2010 and was marked Pending Judicial in May 2015, but does not document the 2023 outcome. The candidate closure date can narrow archival, FOIA, oversight, and docket searches.

Limits: No actual signed DEA closure record, case-status export, prosecutor declination or referral record was found or verified during this sweep. The June 16 date is source-reported, not independently authenticated here; an operation closing date may not be identical to closure of all related investigations. No evidence reviewed proves a decision to protect a target from charges.

Verify: Obtain DEA closing report and case-status history, OCDETF roster disposition, any AUSA declination, interagency investigative referrals, and closure timestamp for C1-11-0049/NY-NYS-0829. Compare any closure against FBI and IRS continuation without equating agency datasets.

Subsequent source audit, C32: The June 16, 2023 date remains attributed to secondary reporting and lacks a recovered DEA status-history export. The 2015 “Pending Judicial” label cannot independently establish imminent indictment.

Medical inventory review identifies additional opioid and syringe entries requiring provenance

Documented: A published item-by-item research account of EFTA00522943 lists tramadol 50 mg, a French opium-containing analgesic, a codeine-containing analgesic, and 3 mL and 5 mL syringes, in addition to the already recorded benzodiazepines and other medicines. A separate independently indexed full-text corpus identifies both EFTA00522943 and EFTA00522035 as overlapping four-page medication lists. EFTA00814713 is separately identified as an email containing informational material about zolpidem/Ambien adverse effects.

Limits: These details were checked against derivative/indexed transcriptions; neither inventory’s full original page image was independently inspected in this sweep. The French-location attribution and the date and custodian of the inventory have not been independently established. A medication list, syringes, and a circulated drug safety article are not evidence that substances were illegally administered to anyone.

Verify: Inspect both original four-page PDF images and the third email; align each medicine, quantity, heading, page, document creation date and context. Seek invoices, legitimate prescriptions or pharmacy ledgers and compare with legally available survivor corroboration only when a causal link exists.

The DEA memorandum cites three financial annexes that are absent from the released 69-page copy

Documented: The original scanned OCDETF report identifies seven Epstein-referenced suspicious activity reports totaling $5,672,921, three unified currency transaction reports totaling $102,648 and eight earlier currency transaction reports totaling $233,397. The text points to Attachment 1 for SAR details, Attachment 2 for CTR details, and Attachment 3 for a separate set of CTRs involving redacted parties. Its 69-page public PDF comprises a six-page front section and 63 report pages; the final page is EFTA00174021. These three supporting financial annexes do not appear in that PDF.

Limits: The missing annexes are not proof of deliberate withholding or destruction. They may have been delivered separately, retained by the originating agency, or omitted from this publication for legal reasons. Underlying SAR narratives are sensitive, may involve confidential subjects and are allegations rather than judicial findings. Do not double-count multi-subject reports as distinct money flows.

Verify: Seek the OFC transmittal and inventory; Attachment 1 USAR schedule, Attachment 2 CTR schedule, and Attachment 3 CTR schedule through the authorized DEA/FinCEN oversight process; match unique BSA identifiers and account ledgers; document exemptions separately. Preserve other targets’ redactions.

DEA profile references separate NCIC inquiry spreadsheets, which are not part of the PDF release

Documented: The report’s Offline NCIC guidance describes supplemental files using the naming format “Offline NCIC Results for Target [date and time].xls” containing inquiry timestamps and agency ORI terminals. It says the page-level table is a summary, and the supplemental Excel records give the exact information an agency would need to locate an underlying query. The reviewed public PDF does not contain those Excel attachments.

Limits: The source explicitly warns that a record of another law-enforcement agency querying someone does not necessarily mean that agency opened an investigative file. The sheets have not been obtained; no specific outside agency or query can be added as an Epstein narcotics finding solely from this general guidance.

Verify: Request the referenced Offline NCIC spreadsheets and cover-sheet inventory; preserve lawful redactions. Compare specific query timestamps and agency identifiers with independently obtained case-opening records, but do not infer a crime or separate investigation from lookup history.

“Pending Judicial” is a recorded case-status field; indictment readiness is unverified

Documented: The DEA/New York case table dates the opening of C1-11-0049 to December 17, 2010, and gives its 2015 status exactly as “Pending Judicial.” The separate OCDETF profile identifies Epstein as Target 4 and was requested on April 28, 2015. This establishes the administrative entry and the sequence of records.

Limits: The status label by itself does not establish a proposed indictment, probable cause finding, grand-jury referral, charging recommendation, or prosecutor declination. Secondary descriptions saying the operation was “on the verge of indictment” exceed what this field proves. The reported June 16, 2023 closing date (C28) still has no authenticated agency disposition instrument in the reviewed source set.

Verify: Obtain case-status codebook as of 2015, the DEA/OCDETF administrative history, prosecutorial referral correspondence, closing memorandum and any USAO review. Distinguish closure of the umbrella operation from disposition of Epstein-specific leads.

Redacted Epstein assistant was linked to a 2014 SAR and foreign-visa sponsorship

Documented: The DEA profile reproduces a FinCEN reference to a 2014 suspicious-activity report involving Epstein and an unnamed associate. It describes the redacted person as his personal assistant who reportedly recruited or facilitated illicit activities and notes that the associate sponsored Target 6 on a State Department nonimmigrant-visa application. This is an intelligence and SAR description, not independently established conduct.

Limits: The person’s name and Target 6 identification are redacted in the released report. Neither may be assigned to any of the 179 roster members by occupational similarity, model references, visa timelines or third-party speculative unredactions. The activity described is not confirmed drug distribution or compelled administration.

Verify: Seek the 2014 SAR identified by BSA number, authorized unredacted DEA target profile, corresponding DS-160 or visa sponsorship records and contemporaneous investigative correspondence, with victim/privacy controls.

179-person matrix reconciliation exposes 77 unreviewed drug-category entries

Documented: The connected master matrix contains 179 named entries: 81 previously screened in Passes 179–180 and 98 subsequent expansion entries. Exactly 21 expansion drug-category rows contain some prior review and 77 explicitly read NOT REVIEWED. The 21 screened rows are mainly narrow or inconclusive; one describes an unrelated federal indictment.

Limits: This is a measure of research coverage, not a finding that any of the 77 participated in drug activity. Other unrelated allegations, personal associations, or professional roles cannot bridge redacted DEA target identities. The October 17 snapshot may not reflect later edits in other branches.

Verify: Conduct systematic person-and-alias screening of the 77 with authenticated documents, then recheck the 21 existing entries and preserve their source scopes. Keep this audit separate from the 85-record DR Atlas until v1.1 is available.

Michael S. Jeffries: charged drug-facilitation conduct in an unrelated federal sex-trafficking case

Documented: The EDNY indictment alleges that staff provided alcohol, poppers and Viagra at events, that men were pressured to consume some substances, and that Jeffries and Smith directed or personally administered prescription-grade erection-inducing injections. These are expressly allegations in a filed indictment, not adjudicated facts.

Limits: The indictment as reviewed does not identify Epstein or establish any link to Operation Chain Reaction. Shared industry, institutional context, or similar coercive tactics do not prove coordinated operations. This case must remain independently labeled and its later disposition checked before asserting outcomes.

Verify: Review the official federal docket for the indictment’s current disposition and compare only original records establishing shared persons, payment flows, communications or facilities, if any are located. Do not infer an Epstein conspiracy.

SLK’s financial-administration records name additional matrix participants without a narcotics finding

Documented: A cross-index of disclosed correspondence references SLK payroll funding in a 2013 email, an October 2014 Deutsche Bank account review, and a July 2013 corporate-date exchange. The source index names or references some personnel also on the 179-person roster, including Paul Morris, Lesley Groff and Bella Kline; an abbreviated “Rich K” reference requires independent identity control.

Limits: Original page images of all three records were not recovered during this sweep. Some records are described by a derivative cross-corpus report; the quoted context therefore remains provisionally attributed. Payroll arrangements, bank account review and company formation alone do not establish narcotics activity, laundering or identity as a redacted DEA target. The derivative index uses “Bella Klein,” while the connected master matrix has “Bella Kline”; their identity must not be equated without original correspondent identifiers.

Verify: Recover EFTA01893906, EFTA01423319 and EFTA02131473 as original pages; authenticate correspondent fields, signed ownership revisions, bank opening outcomes and posting dates. Match any alleged drug-related funds only through transaction-level source documents.

2010 Hoffenberg FBI interview ended without substantive Epstein statement

Documented: An FBI electronic communication records that agents approached Steven Hoffenberg on October 12, 2010. He declined to answer questions about Epstein or an unrelated homicide topic without court-appointed counsel and stated that he would speak after counsel was provided. The source records no substantive account of narcotics or Epstein financial transactions from that interview.

Limits: The electronic communication bears a 2019 drafting date while describing a 2010 interview; these are distinct dates. The item does not establish that a drug investigation involved Hoffenberg, nor explain whether he was subsequently re-interviewed. Original PDF-image inspection remains a separate quality-control requirement; the present examination used a released-document text transcription.

Verify: Retrieve the underlying 2010 field notes, the draft/approval history, and follow-up interview records by FBI case 72-MM-NEW; reconcile with financial and Towers investigative records, without merging with DEA Chain Reaction.

2019 Hoffenberg FBI tip concerned alleged securities fraud, not identified narcotics proceeds

Documented: FBI National Threat Operations Center intake reports that Steven Hoffenberg called on July 8, 2019. He asserted that Epstein had committed securities fraud during the Towers Financial years and claimed the money used for Epstein’s defense was tainted. The document also points to a civil lawsuit. This verifies the existence and date of his report, not the truth of the fraud assertions.

Limits: The intake contains allegations supplied by Hoffenberg and does not establish an investigated narcotics-related transfer, a DEA target role, or a judicial conclusion. Text extraction has a malformed date in one header; the “Date/Time Received” field states July 8, 2019. Original image not independently compared in this sweep.

Verify: Locate the original FBI intake and any referral or investigative disposition; compare the actual securities case, financial instruments and fund flow chronology with the DEA memo’s dated BSA reports. Do not equate securities allegations with controlled-substance financing.

Jeffries sex-trafficking trial moved to January 2027; no verified Epstein operational link

Documented: The October 2024 EDNY indictment alleges that staff supplied alcohol and other substances during commercial-sex events. On August 20, 2026, Judge Choudhury found Michael S. Jeffries competent to stand trial. At an August 27 hearing the court reset trial commencement to January 4, 2027, replacing the earlier October 26, 2026 date. The three defendants pleaded not guilty.

Limits: These remain charges and assertions in a distinct criminal case. No verified Epstein communication, joint financial instrument, shared event or common defendant links this case to Chain Reaction. The court schedule may later change; a new docket check is required before publication.

Verify: Confirm subsequent trial-date changes against the federal docket and examine only source-established overlaps. Keep drug-facilitated-abuse allegations in this charged case separate from Epstein-specific narcotics findings.

Fifteen investigative targets include two businesses: avoid “14 co-conspirators” characterization

Documented: The source memorandum table of contents identifies Targets 1–15. Targets 14 and 15 are organized under Business Identifying Data, while Epstein appears as Target 4. A February 2026 Senate inquiry describes the 14 remaining targets as “co-conspirators”; that assertion goes beyond the public profile and conflates investigative target designation with adjudicated criminal participation. At least two numbered targets are business entries, not necessarily individuals.

Limits: Names and corporate identities of the other targets are substantially redacted. The existence of a target profile does not prove criminal conspiracy, that the targets participated in one offense, or that drugs were trafficked. Senator Wyden’s language is his characterization, not an adjudicated finding.

Verify: Retrieve an unredacted target-status key through lawful oversight channels, underlying intelligence attachments, charging-review and closing records. Do not re-identify redacted subjects by job title or neighborhood.

Banasiak named in 2006 Washington Mutual records subpoena; bank later reported enclosed materials

Documented: An August 2, 2006 grand-jury subpoena sought Washington Mutual applications, signature cards, correspondence, 2004-onward billing statements and repayment instruments associated with Epstein, Janusz Banasiak and Alfredo Rodriguez. An August 24, 2006 Washington Mutual response says it enclosed records located in response to the subpoena.

Limits: This document shows a lawful evidence request and a bank response, not the detailed transactions themselves, any narcotics allegations, personal criminal responsibility, or any connection to the separate case C1-11-0049 opened in 2010. The underlying scans require authentication against the DOJ original and redacted personal identifiers must be excluded.

Verify: Acquire the actual records produced with the Washington Mutual response and applicable grand-jury disclosure authorization. Compare dates and instruments with later lawfully obtained financial records only if a common transaction identifier emerges.

Tova Noel’s federal prosecution concerned correctional-record falsification and was dismissed

Documented: The signed January 3, 2022 order in United States v. Noel and Thomas states that defendants were charged in 2019 with conspiracy to defraud the United States and false statements under 18 U.S.C. §§ 371 and 1001. Prosecutors recorded completion of deferred-prosecution requirements and the court ordered nolle prosequi. The charged conduct concerned correctional records, not controlled substances.

Limits: This is an exclusion for the identified prosecution only and does not constitute a comprehensive investigation of every episode in Noel’s life. It is distinct from Epstein’s crimes and Chain Reaction. Court disposition cannot establish a narcotics link by virtue of appearing in Epstein-associated records.

Verify: Keep the signed filed order and court docket as controlling proof of disposition. Do not misclassify the former charges as narcotics conduct; do not imply that dismissal speaks to unrelated unknown activity.

Faith Kates emails concern prospective compensation and a research referral, without drug procurement

Documented: A March 2014 message exchange between Faith Kates and Epstein refers to possible fees or equity in a business introduction. A separate April 2010 correspondence sends a medical-research website and relays claims from another person. The messages document professional communication and scientific interest; neither identified message is a medication order, shipment record, narcotics payment or evidence of drug administration.

Limits: This is a bounded two-document screen. It neither exonerates Kates of unrelated allegations nor establishes involvement in drug activity. The third-party claims about treatment effects in the 2010 message are unverified. The corpus is broader than two emails.

Verify: Continue full communications/procurement matching only on original dated item identifiers; seek transaction-level evidence before attributing controlled-substance conduct. Preserve researcher and recipient identities where privacy protections apply.

Epstein defense materials used alleged witness drug use to contest credibility, not to prove trafficking

Documented: A released 2007 memorandum from Epstein defense counsel addressed to federal prosecutors discussed witnesses’ online statements and alleged drug use to attack credibility. A later court-filed copy provides the disputed defense argument. A published court transcript describes a witness confirming that alcohol or marijuana references at a meeting were used to question credibility. These are source-documented legal tactics, not proof of wrongdoing by the survivors.

Limits: The defense memo contains contested assertions about young witnesses. Those assertions are not adopted as fact or reproduced as identifying detail. A defense submission is advocacy, not a court finding. The drug references do not connect the witnesses to DEA Operation Chain Reaction, which opened in 2010.

Verify: Compare the defense letter with contemporaneous police interviews, the full witness deposition and federal prosecutors’ documented decisions. Preserve survivor confidentiality. Reconstruct whether any drug-related credibility theory altered evidence access or charging without assuming motive.

Epstein motion to exclude evidence identified seized lotions and medical-document categories, not toxicology findings

Documented: A motion in limine filed on Epstein’s behalf lists categories from opposing counsel’s revised exhibit list, including lotions collected from Epstein’s residence during a search, a general search-evidence inventory, and medical-document categories. The filing establishes that these evidence categories were disputed in civil litigation. It does not contain tested pharmaceutical inventory values or medical results.

Limits: A motion seeking exclusion is not a ruling admitting, excluding or authenticating the underlying objects. Lotions cannot be reclassified as sedatives or controlled drugs. The identities and medical histories of survivor witnesses are excluded from the public-facing Atlas. Nothing here establishes drug administration or narcotics financing.

Verify: Recover original police property reports and laboratory submissions, if any, with appropriate privacy safeguards; look for tested evidence identifiers rather than inferring a drug finding from a generic exhibit title.

Daniel Siad named Jean-Luc Brunel in a July 2010 proposed Ibiza modeling gathering

Documented: A released one-page July 16, 2010 email from Siad to Epstein refers to an intended Ibiza gathering, models, Jean-Luc Brunel and an MC2 business-network proposal. A later public federal docket exhibit list describes a March 3, 2016 communication about Siad among contacts with prosecutors, but marks that exhibit sealed. These are separate dated network and investigative-context anchors.

Limits: The 2010 email does not prove the proposed gathering took place, who attended, the ages of individuals, or any drugs, drug delivery or criminal conduct. The sealed 2016 exhibit list does not disclose the content. The 2010 communication predates the December 2010 opening of Chain Reaction; no DEA cross-reference has been established.

Verify: Check airline, venue and timestamp records only through authenticated lawful documents; pursue any lawfully accessible redacted docket summary for Exhibit O without trying to infer sealed contents. Keep C46 classified as network chronology, not narcotics participation.

A 2010 Richard Kahn email itemizes 2009 payments linked to Peggy Siegal and two ambiguous medical descriptors

Documented: The released email lists six 2009 payments totaling $108,399 associated with Peggy Siegal, including two line-item categories transcribed as “zircon gene - medical” ($13,237) and “bvba anca - medical” ($15,288). It shows an internal accounting description and illustrates a dated connection between two people in the master roster.

Limits: This is a copied email list, not bank confirmation of recipient or invoice purpose. The terms “medical” and “gene” are ambiguous, and neither identifies a narcotic, controlled drug, pharmaceutical, healthcare crime or Chain Reaction activity. A later, unrelated 2017 gift correspondence is not evidence of trafficking either.

Verify: Retrieve the two invoices, named vendor registrations, any corresponding bank debits and service descriptions. Keep any medical-science business context separate from regulated-substance procurement until confirmed at item level.

Court stipulation names Lewis Pharmacy and Greens Pharmacy as 2009 prescription-record subpoena targets

Documented: An Epstein-versus-Edwards joint pretrial stipulation identifies two nonparty pharmacy requests for Epstein’s complete prescription printouts: Lewis Pharmacy and Greens Pharmacy, with contemporaneous exhibits M.97 and M.100 dated August 14, 2009. The same stipulation §47 identifies 2009 requests for physicians’ medical files. This establishes identified subpoena recipients and categories sought, not returned records.

Limits: Paragraph 48 says “August 14, 2019” despite the stipulation anticipating a 2018 trial and separately citing “8/14/09” in its parenthetical. Treat this as a source-internal date discrepancy, not as a verified 2019 issuance. No received prescription list, medicine, quantity, controlled-drug classification or survivor-specific administration has been established.

Verify: Obtain source notice exhibits M.97/M.100 and any returns or objections from Lewis and Greens; reconcile the 2009/2019 discrepancy against clerk-stamped copies, while protecting medical and survivor information.

Lesley Groff coordinated Epstein’s Clyde Chemists prescription pickups in July 2016

Documented: A July 26, 2016 chain between Lesley Groff and nurse coordinator Amanda Antonucci discusses two prescriptions electronically sent to Clyde Chemists for Epstein. Groff reports “we picked up both prescriptions” while coordinating scan appointments and follow-up questions with a urology office. The chain documents administrative involvement in collecting medication for Epstein.

Limits: The two prescribed products are not named in these excerpts. Nothing links them to controlled substances, drug-facilitated sexual assault, a survivor, a fraudulent prescription, DEA Chain Reaction, or Groff’s role as a DEA target. Do not conflate routine medical administration with trafficking.

Verify: Check authenticated contemporaneous prescription identifiers and receipts if lawfully available; compare dates and pharmacy providers with existing medication inventories, without disclosing private patient identifiers.

Repatha injection correspondence documents a proposed cholesterol treatment, not narcotics distribution

Documented: A ten-page email chain refers to Repatha as a prescribed cholesterol-lowering injection, discusses possible training, insurance versus private pay, a drug-company reimbursement program, and possible shipment from Century Specialty Pharmacy. A clinician gives indicative prices of $1,250 per month for one monthly regimen and $1,150 per month for a twice-monthly regimen before a possible discount.

Limits: The emails do not prove the product was ultimately purchased or administered. Repatha is not itself evidence of a sedative, incapacitating drug, narcotics trafficking or illicit injection. The quoted figures were proposed purchasing terms, not verified expenses. No private contact information is included in this display.

Verify: Obtain the signed prescription/dispensing and payment records if lawfully obtainable and relevant. Reconcile with the separate inventory without treating medical terminology as a crime indicator.

BOP reconstruction distinguishes documented 2019 jail medications from earlier private medical history

Documented: The BOP report records medications listed during Epstein’s July–August 2019 confinement: docusate sodium, milk of magnesia, omega-3, methylprednisone, bisacodyl and an insulin entry flagged in the report as lacking a dose indication. It notes pharmacy administration procedures and that contemporaneous Florida incarceration records were unavailable to the review team.

Limits: The report recounts limited BOP medical-record entries and should not be treated as Epstein’s lifetime medication history. An insulin order entry does not establish routine dosing. Nothing in this report identifies a narcotics inventory, confirms intoxicant administration to another person or supports a drug-trafficking allegation.

Verify: Classify by date and care setting. Do not merge 2019 custodial self-carry medicines with 2009 third-party pharmacy requests or 2016/2018 private treatment correspondence.

USVI sought Bear Stearns anti-money-laundering file and cited Greenberg–Epstein contacts around 2010–2011

Documented: In the USVI litigation against JPMorgan, plaintiff counsel sought Bear Stearns AML case files, communications involving Ace Greenberg and Epstein, and additional records of a possible late-2010/early-2011 relationship. The letter describes documents alleging that Greenberg sought an exception to the bank’s felony-client policy and that he contacted Epstein in January 2011.

Limits: This is the USVI’s litigating position and discovery request, not a judicial finding that a bank policy was unlawfully waived, that money funded drugs, or that Greenberg was part of Chain Reaction. The described January 2011 communication occurs after Chain Reaction opened but timing alone is not evidence of investigative overlap.

Verify: Obtain the specified JPM-SDNYLIT email exhibits and Bear Stearns AML case file if publicly and lawfully available; identify the exact policy decision date, responsible signatories and relevant transactional IDs, without presuming narcotics conduct.

JPMorgan’s June 2023 letter contests requests to reopen Jamie Dimon deposition about Epstein compliance

Documented: JPMorgan told the court that Dimon testified he had no contemporaneous awareness of Epstein, argued that none of ten cited communications came from his custodian files, and disputed the USVI’s argument that a 2019 internal compliance summary called Project Jeep may have been ordered by him. The filing confirms that these competing accountability claims were litigated.

Limits: The defense letter is advocacy, not a judicial finding that Dimon lacked knowledge, nor that he possessed it. It does not identify controlled substances, illicit narcotics flows or DEA Chain Reaction communications. A CEO’s institutional position cannot substitute for person-specific involvement.

Verify: Read original deposition exhibits, Project Jeep summary and linked compliance records. Separate disputed bank-supervision responsibility from any demonstrable Epstein-linked narcotics money flow.

Epstein Wall Street Records Act would open federal financial-supervision files if enacted

Documented: The original 2026 legislative text specifies federal bank and securities regulators, including Federal Reserve, OCC, FDIC and SEC. Section 2(b) would require covered supervisory records to congressional committees within 90 days and searchable public records within 120 days, measured from a future enactment. Section 2(c) would require regulator investigations of institutions and responsible executives, including controls, transactions and possible destruction of records. The public release provision expressly protects victim-identifying and medical records.

Limits: This is proposed legislation; the cited 90/120/180-day deadlines are not currently enforceable and are conditioned on enactment. It neither releases unrecovered Chain Reaction attachments nor establishes that a person or bank funded a narcotics operation. Existing SARs remain a separate evidentiary category from regulator examination files.

Verify: Track the official legislative status and obtain authenticated supervisory records only if subsequently released. Build a separate registry for agency examiner notes, supervisory communications, internal compliance correspondence and decisions concerning Epstein-related accounts; do not infer that unavailable records contain drug transactions.

Erika Kellerhals named co-trustee of Epstein’s 2013 Butterfly Trust

Documented: A 23-page trust instrument dates the Butterfly Trust to December 31, 2013, names Epstein as grantor, and appoints Erika A. Kellerhals and Richard Kahn as trustees. The discretionary-beneficiary paragraph lists named members of Epstein’s professional and personal network, and Schedule A records an initial $100. The document establishes the designated fiduciaries and terms of a documented trust instrument during the 2010–2015 Chain Reaction window.

Limits: Trustee designation, discretionary authority, and the $100 initial schedule do not establish later balances, actual disbursements, money laundering, narcotics procurement or any connection to the DEA operation. The text contains no identified illicit drug transaction. Some people appear as possible beneficiaries without proof of payment. This record is financial/structural context, not an assignment of drug wrongdoing to Kellerhals or Kahn.

Verify: Compare only authenticated executed amendments, trust asset and distribution statements, court-filed account schedules and financial instruments if lawfully available. Reconcile named fiduciaries with already indexed financial-record lanes while protecting unrelated private beneficiary data.

James Cayne named in Epstein-related Bear Stearns investment dispute, with an earlier brokerage-record reference

Documented: A verified civil complaint filed in the U.S. Virgin Islands in August 2009 alleges Epstein spoke by telephone with Bear Stearns executive James Cayne on August 6, 2007 about selling 120,000 Bear Stearns shares. The plaintiff alleged Cayne recommended holding the position and made assurances about firm liquidity. A separate 2001 Bear Stearns brokerage account statement identifies “CAYNE, JAMES E.” in the printed account-executive field for an account labeled International Charitable Interests II and lists an approximately $2.10 million repurchase-agreement principal. These source items establish specific documentary claims and an older account-reference entry.

Limits: The complaint recounts the plaintiff’s disputed account of conversations and is not a judicial finding that Cayne committed fraud. The 2001 statement has not been matched to an Epstein-owned legal entity or disbursed drug proceeds by this review. Neither source identifies controlled-substance purchases, Chain Reaction case activity, or personal involvement in drug-facilitated abuse. Account identifiers and contact details have been omitted.

Verify: Retrieve the case docket and any dispositive settlement or order; reconcile whether the named account owner was controlled by Epstein using original entity/account authorities. Keep the 2001 account statement separated from the 2010–2015 DEA reporting cutoff and never count civil investments as narcotics flows absent transaction-level proof.

Court narrowed access to Project Jeep and recipient payment records

Documented: The court partly granted the USVI motion to compel: JPMorgan was directed to produce financial records for specifically identified new recipients of Epstein payments within five business days of a qualifying request, or confirm prior production. The court declined to compel production of all Project Jeep materials or all post-arrest internal investigation records, and denied sanctions.

Limits: The order does not establish whether the USVI later supplied a qualifying recipient list, whether JPMorgan produced every requested document, or whether any payment had a drug-related purpose. Financial account records are distinct from the unrecovered DEA Chain Reaction SAR annex and its closure record.

Verify: Obtain docket 212 and any compliance correspondence or certified production log; compare account and transaction identifiers only where lawfully public. Keep identities of private recipients and survivors out of the public-facing exhibit.

Project Jeep email names a combined communications-and-transactions chronology

Documented: A disclosed October 27, 2019 internal JPMorgan message from Brian Filbert reports an electronic-communications review regarding Epstein and Staley, and says a colleague prepared a timeline combining electronic communications with relevant transactional activity. The exhibit describes a small set of examples the review team considered and states the analysis was ongoing.

Limits: The exhibit documents a compliance workflow and the existence of combined analysis. It does not authenticate the full underlying transaction ledger, establish illegal drug purchases, name DEA targets, or show that the bank investigated Operation Chain Reaction.

Verify: Seek the referenced combined timeline, the linked e-communications summary JPM-SDNYLIT-00901998, and any matching transaction source records available in public court exhibits. Do not publish recipient-identifying banking information.

John W. Kessler: shareholder case identifies governance position and its failed pleading

Documented: Kessler was named as a former JPMorgan director in a 2023 shareholder derivative case concerning the bank relationship with Epstein. Defendants disputed plaintiffs’ attempt to connect Kessler’s New Albany relationship and board history to Epstein oversight. In January 2024, the court dismissed the derivative action with prejudice for failure to meet the demand-futility pleading requirement.

Limits: The allegations against Kessler were contested and did not produce a finding that he participated in drug trafficking, knew of drug-facilitated abuse or directed a bank policy violation. Dismissal of this shareholder case does not decide every distinct claim about the bank or provide the DEA operation outcome.

Verify: Preserve the court’s procedural basis for dismissal alongside the contested allegations. Seek only role-specific board minutes or bank oversight records that were actually made public; do not infer a criminal connection from New Albany property associations.

Sandy Warner: USVI filing attributes an early Epstein introduction to the bank executive

Documented: In a summary-judgment submission, the USVI asserted that Warner, then a senior JPMorgan executive, recommended Epstein to Jes Staley around 2000, describing Epstein as particularly well connected. The submission cites a separate statement-of-undisputed-facts paragraph 275 for that account.

Limits: This is an adversarial filing stating the USVI’s position. Without the underlying testimony or an accepted stipulation, the alleged quotation should remain attributed. Neither the asserted introduction nor senior-bank position is evidence of narcotics procurement, money laundering or participation in Operation Chain Reaction.

Verify: Retrieve and cross-check the underlying SUF paragraph 275 citation, any deposition testimony, and any defendant response to the factual statement. Screen Warner as a historical banking-contact lead only, leaving the drug-misconduct classification unsubstantiated.

Late-filed bank alerts must be reconciled with the seven 2015 DEA-listed SARs

Documented: The Senate report records JPMorgan September 26, 2019 retrospective reporting of 4,725 wires totaling approximately $1.1 billion and an August 13, 2019 filing covering 469 wires totaling $201 million. It also cites Deutsche Bank retrospective reporting of 1,140 wires totaling $147 million and Bank of America reporting about $170 million of Leon Black payments in 2020. The 2015 OCDETF profile separately lists seven SARs totaling $5,672,921.

Limits: Bank SAR totals are suspicious-activity reports, not findings that every transfer was unlawful. Reporting windows, covered institutions, underlying transaction lists, and possible overlaps between filings have not been reconciled. The 2015 seven SARs cannot safely be assigned to JPMorgan or added to later aggregates. The sources do not identify controlled-substance purchases within these totals.

Verify: Acquire original SAR identifiers, filer names, transactions and inclusive date windows. Build a deduplicated transaction key using filing ID, originating bank, transaction date, currency, amount, originator and recipient. Request the missing Chain Reaction Attachment 1 and compare only authenticated common transfers.

Forensic account map identifies 134 JPMorgan accounts and $78 million of unusual activity

Documented: A court-filed forensic-accounting expert report identifies 134 JPMorgan accounts classified as 6 Epstein personal accounts, 59 Epstein-controlled or trustee-held entity accounts, and 69 accounts for related individuals or entities. The expert identified more than $78 million of transactions he regarded as unusual, including cash use and payments with uncertain business purposes. He stated that complete financial documents for the related accounts had not been received.

Limits: The report expresses a retained expert’s opinions in adversarial litigation; it is not an adjudication. The $78 million is a defined analytical subset and must not be added to the later $1.4 billion suspicious-activity reporting aggregate. Some accounts and transactions involve other people; no classification here establishes a controlled-substance payment, drug-facilitated abuse, or identity among the redacted DEA targets.

Verify: Use Exhibit C and the July 1, 2013 JPMorgan Subject Client Review (JPM-SDNYLIT-00029203–00029211) as inventory keys. Compare only lawfully public transaction-level records against the DEA case identifiers; exclude private account numbers and survivor-linked personal transaction details from display.

BNY Mellon inquiry identifies 270 wires totaling $378 million and asks about 18 repeated $1 million transfers

Documented: Senate Finance reported that a 2019 BNY filing covered 270 Epstein-related wires totaling approximately $378 million, and its written inquiry asked about at least 18 round-dollar $1 million transfers in 2007. It requested copies of SARs, dated payment instruments, account signatory information and the bank’s internal review findings.

Limits: The release establishes the contents of a congressional inquiry and staff-reported filing. It does not supply 270 individual transfers or prove their purpose, and the 18 queried wires cannot yet be matched to the DEA 2015 SARs. Asking why payments occurred is not a finding of drug trafficking. Do not aggregate the $378 million with other banks without identifying duplicate correspondent flows.

Verify: Find the underlying 2019 BNY SAR and lawful bank response, identify the 2007 $1 million instrument dates and counterparties, then cross-check correspondent-bank entries and any included DEA suspicious-activity identifiers.

Melanie Spinella: 2014 correspondence establishes expense and power-of-attorney coordination

Documented: An extracted February 2014 email chain involving Epstein, Richard Joslin and Spinella discusses how Leon Black household, charitable, legal and other expenses would be handled between family-office personnel and Spinella. A separate March 2014 chain discusses preparation and signing of power-of-attorney forms. The records support a financial-administration and document-routing role.

Limits: Neither chain identifies a controlled drug, pharmaceutical dispensing event, illicit narcotics transfer or involvement in the DEA case. An expense category labeled medical is not a medicine purchase or evidence of abuse. These are searchable extracts of DOJ release pages; original scanned-page authentication is still pending for sensitive or contested wording.

Verify: Verify the original pages at the listed Bates numbers and the signed instruments, if public, before ascribing legal signing authority or financial approval to Spinella. Maintain separate identities and duties across the Black and Epstein offices.

Dennis Hersch: successor power of attorney and foundation trustee roles have separate timelines

Documented: In his February 2026 written statement, Leslie Wexner identified Hersch as the personal-finance successor to Epstein and said he gave Hersch the same scope of power of attorney he previously granted Epstein. The Wexner Foundation-commissioned review lists Hersch as a foundation trustee beginning in 2008 and as a person interviewed during the review.

Limits: A first-person assertion of equivalent delegated authority does not establish executed documents, exact periods, asset transfers, drug activity or any role in Chain Reaction. The foundation trustee position began after Epstein resigned from the foundation in 2007; it cannot be presented as overlapping trustee service.

Verify: Obtain signed powers of attorney and effective/revocation dates if legitimately public; distinguish Wexner personal finances from the foundation’s separate governance and accounting processes.

Peg Ugland: family-office accounting duties are distinguishable from Epstein personal conduct

Documented: The Foundation-commissioned 2020 review identifies Ugland as a long-serving Wexner Investment Company / N.A. Property controller and vice president with finance, accounting and human-resources oversight, including some Foundation accounting. It lists a Foundation treasurer role beginning in 2009. The review also states the foundation relied on N.A. Property for accounting and tax administration.

Limits: The scope reflects the review’s records and interviews, not a direct payment ledger for Epstein-associated individuals. It cannot establish that Ugland knew or controlled Epstein’s financial activity, supplied pharmaceuticals, or participated in Chain Reaction. The report found little meaningful personal involvement by Epstein in Foundation accounting, subject to its review’s limited scope.

Verify: Reconcile actual account signatories, fund transfers, and delegated duties against publicly released instruments before assigning a transaction to any officer. Do not treat shared service-provider employment as evidence of misconduct.

Targets 14 and 15 are business records within the fifteen-target DEA profile

Documented: The memorandum profiles fifteen targets, with Jeffrey Epstein as Target 4. The contents give Targets 14 and 15 BUSINESS IDENTIFYING DATA sections, distinguishing these two profiles from the person-oriented biographical sections of other targets. Their names remain concealed.

Limits: The profile establishes a target structure, not a finding of guilt. It is inaccurate to characterize every redacted target as an individual associate or to assume any business identity from the headings.

Verify: Seek lawful unredacted target-type classification, original case database and evidence of any transaction attributed to each entity. Do not speculate about redacted identities.

Four 2014 commercial-airline crossings identify exact New York and Paris travel dates

Documented: The CBP table lists JFK to Paris Charles de Gaulle on February 9, 2014 (Air France 009); Paris to JFK on February 19 (Air France 022); JFK to Paris on April 29 (Air France 011); and Paris to JFK on May 6 (Air France 006). They appear in Epstein's Target 4 profile.

Limits: Passenger travel does not establish drug transport, the purpose of the trips, accompanying travelers, or involvement in a French judicial inquiry. Commercial flights should not be merged with private-aircraft movements.

Verify: Reconcile CBP movement entries with contemporaneous manifests and publicly authenticated itineraries, preserving the difference between travel dates and activities alleged in another document.

A 2013 Paris ICE inquiry has its own case identifier and closure date

Documented: The OCDETF target profile lists an ICE/Paris, France case identified as PA07QK13PA0002, opened June 7, 2013 and closed October 3, 2013, categorized as Operation Angel Watch and registration/transiting information sharing. The entry cites ICE reporting on the 2008 Florida conviction.

Limits: This ICE entry predates the 2014 commercial flights, and its closure is separate from the DEA Chain Reaction case disposition. It does not establish an independently investigated French drug offense or any medication supply chain.

Verify: Locate the publicly releasable ICE ROI PA07QK13PA0002-003, then reconcile dates and specific actions without substituting the Paris entry for a French prosecutor record.

Abigail Wexner: financial-account review and 2007 authority changes are separately dated

Documented: Leslie Wexner stated that Epstein discussed his legal difficulties with Abigail in late 2006 and supplied financial information in 2007, after which she identified what the family regarded as misappropriated assets. He described revoking Epstein's power of attorney in September 2007 and severing access to family accounts. This is Wexner's account of events, not an authenticated ledger or court finding.

Limits: The statement does not establish the value of misappropriation, a particular transaction or any link to narcotics. Abigail's involvement in family financial review is a reported governance role, not evidence of wrongdoing.

Verify: Compare the asserted revocation and transfer chronology against publicly filed powers of attorney, dated asset records and independently authenticated source instruments. Keep allegation and established execution distinct.

Robert Meister: Wexner identifies him as an early Epstein introduction

Documented: Leslie Wexner named Bob Meister, formerly vice chairman of Aon, as the person who introduced him to Epstein in the mid-to-late 1980s while he was seeking personal financial advice. The statement also describes independent references from other financial industry contacts.

Limits: The statement is a later first-person account of an introduction, not a 1980s contemporaneous record. It supplies no evidence that Meister was aware of Epstein's later conduct or connected to Chain Reaction, drug supply, or bank transaction processing.

Verify: Retain exact attribution to Wexner and seek contemporaneous records only if lawfully public. Do not use an introduction to ascribe criminal knowledge or conduct.

Harold Levin: named as financial adviser preceding Epstein

Documented: Leslie Wexner described his sequence of personal financial advisers as Harold Levin, Jeffrey Epstein, Dennis Hersch, and later Abigail Wexner with an outside multifamily office. The statement establishes that Wexner publicly identified Levin as an earlier adviser.

Limits: The statement does not provide the dates of Levin's actual engagement, account signatory powers, payments or personal involvement in Epstein activities. No narcotics finding can be drawn from the predecessor role.

Verify: Seek executed engagement and succession documents if publicly released. Distinguish a historical professional appointment from liability for actions by subsequent advisers.

French prosecutors requested US case materials after documenting the 2019 Paris evidence seizure

Documented: The original French request identifies a September 23, 2019 search of Epstein’s Paris premises and describes seized computers, storage devices, electronic correspondence and a spreadsheet of 62 female names. It asks American authorities to supply interviews, seizure records and forensic examination results relevant to Jean-Luc Brunel and Ghislaine Maxwell. The document also summarizes incapacitation accounts already indexed in C03.

Limits: The request does not contain the US response, source-file inventory, toxicology returns or a DEA Chain Reaction cross-reference. An indexed list of names is not proof those people were survivors. C03 and its English-language translation remain the same source family, not additional independent testimony.

Verify: Seek the French assistance request transmission log and US receipt/response records, judicially releasable digital-forensic inventory, and case-number correspondence. Preserve redactions and avoid reproducing any private person’s identity.

French judicial request gives inconsistent August 2019 investigation opening dates

Documented: The opening Investigative Framework (Cadre d’enquête) describes a preliminary investigation opened August 30, 2019. The Exposé des faits narrative reports that the Paris minors section opened its preliminary investigation on August 23, 2019. Both dates appear in the same original seven-page request.

Limits: The discrepancy could reflect separate administrative steps, a copying error or the timing of a related inquiry. Nothing in the published document establishes which date is the formally docketed date. Do not combine the two into a fabricated chronology.

Verify: Match the Paris prosecutor registration entry, dated initiation order and OCRVP intake referral under reference 19 235 449. Record any distinct procedural opening dates if supported.

Wexner Foundation review records Epstein’s formal approval of grants during 1993–2004

Documented: The commissioned legal review dates Epstein’s Foundation trustee service to December 15, 1992 through September 4, 2007. Its authors say reviewed grant agreements reflect his formal approval of annual Wexner Foundation grants to the Wexner Heritage Foundation for 1993–2004 and of periodic corporate board actions. They separately report interviewees’ accounts that Epstein did not run programs or accounting.

Limits: The report describes signed records without reproducing a complete execution index or account-level disbursements. A formal trustee approval does not establish control over recipient bank transfers or involvement in narcotics. The review was commissioned by the institution whose conduct was examined.

Verify: Obtain dated original board resolutions, grant agreements, Form 990-PF schedules, banking signatories and disbursement instruments; map grant approvals against actual disbursement dates. Maintain separation between signatures, operational supervision and criminal conduct.

Produce Epstein Treasury Records Act draft names specific trusts and people but creates no finding of misconduct

Documented: The published seven-page draft would require Treasury to supply certain Epstein-related suspicious activity reports within 30 days of enactment. Its included-person-and-entity list identifies Scott Borgerson, Bella Wexner and numerous financial institutions or trusts. The document also includes other listed people who were previously screened in the 179-person roster.

Limits: The PDF contains placeholder bill-number and introduction fields. It does not demonstrate introduction, enactment, completion of record production or that every named person transacted with Epstein. The draft’s broad scope creates a records-acquisition target rather than an individual narcotics allegation.

Verify: Identify the formally introduced Senate bill, if any, and distinguish its provisions from the separate October 2026 Wall Street Records proposal in C54. Seek lawfully released records only after identifying actual authority and specific instruments.

Scott Borgerson appears in proposed Treasury-records disclosure scope

Documented: The Senate Finance draft lists Scott Borgerson in its proposed set of Epstein-associated individuals and entities for Treasury records retrieval. This establishes an express legislative disclosure-scope reference, with a traceable source and position in the original draft.

Limits: The listing neither identifies an account nor establishes a transaction, controlled drug, drug-facilitated abuse, money laundering or responsibility for Ghislaine Maxwell’s activities. A proposed statutory list is not evidence of culpability.

Verify: Locate lawfully public instruments or dated bank correspondence actually identifying Borgerson as a party before assigning a transaction or accountability edge.

Bella Wexner is named in disclosure proposal without an identified drug transaction

Documented: The published draft names Bella Wexner between Les Wexner and Abigail Wexner in its proposed Treasury-records subject list. The document itself does not set out the reason for that person-specific listing or attach financial evidence.

Limits: Identity, family relationship and a list entry do not establish account authority, a transferred payment or criminal knowledge. No controlled-substance connection is shown.

Verify: Resolve the exact identity and any relevant formal signatory or beneficiary instrument from lawfully public documents before classifying an actual financial edge.

Larry S. Moses: leadership overlaps Epstein trustee years; interview describes no meetings

Documented: The report identifies Moses as Foundation employee from 1987 to 2011, vice president 1993–1998 and president 1998–2011. The report attributes to him a statement that he had never met or personally contacted Epstein, although Epstein was a formal trustee until September 2007. Foundation accounting was handled through a separate family-office department.

Limits: His account is interview testimony as summarized in a Foundation-commissioned review. It does not authenticate all communications or disprove unobserved interactions, and no narcotics conduct is attributed to Moses.

Verify: Locate dated Foundation board and grant approvals and original review interview records if released, while distinguishing oversight responsibilities from independent bank operations.

Rabbi Maurice Corson: 1985–1998 foundation presidency documented

Documented: The commissioned review identifies Corson as Foundation president from 1985 through 1998 and among its interviewees. His leadership overlaps the start of Epstein’s formal trusteeship in 1992.

Limits: Institutional chronology is the scope of this finding. The cited material does not describe drug purchasing, trafficking, a financial authorization by Corson for Epstein or his personal awareness of Epstein misconduct.

Verify: If accounting responsibility becomes material, seek original dated institutional actions identifying the specific authorized parties, rather than assigning liability from a shared institution.

Rabbi Nathan Laufer: separate Wexner Heritage leadership before its 2005 merger

Documented: The review lists Laufer as a Wexner Heritage Foundation employee from 1986 to 2003, including program director, vice president and president/CEO roles. Wexner Heritage was a distinct charitable organization until its 2005 merger into the Foundation.

Limits: Overlap of program leadership with Epstein’s trustee appointment does not establish contact or funding authorization. The source provides no support for a narcotics link.

Verify: Keep the pre-2005 Heritage Foundation organizational records distinct from the Wexner Foundation when reconstructing grant signatures and administrative responsibilities.

Two 2009 pharmacy production notices anchored to exhibit numbers

Documented: The 2018 court filing indexes the August 12, 2009 Greens Pharmacy request as exhibit 18-3 and the August 14, 2009 Lewis Pharmacy request as exhibit 18-4. The same requests reappear in its later exhibit schedules. They were discovery notices in an earlier civil suit, not an inventory of medication.

Limits: The index establishes that requests existed and identifies dates. It does not contain the pharmacies’ produced ledgers or show whether production occurred; it establishes no controlled-substance use or dispensing.

Verify: Obtain the actual 2009 notices, service and responses, any sealed/protective-order ruling and lawfully public pharmacy production logs, without exposing private medical information.

Epstein’s August 20, 2009 objection followed the pharmacy notices

Documented: The litigation exhibit index identifies an August 20, 2009 filing captioned Epstein’s objections to third-party production notices and incorporated motion for protective order. It followed the pharmacy requests in the index chronology.

Limits: The indexed caption alone does not prove the objections targeted each pharmacy specifically, that a court granted protection or denied discovery, or that the requested records existed.

Verify: Inspect the complete August 20 filing, any associated hearing or written ruling, and docketed notice of compliance. Preserve distinctions among objection, order and actual return.

The 2001 Arts Interests Trust receipt was attributed to Wexner-funded assets

Documented: The Foundation’s 2001 filing listed $9,588,560 from an Arts Interests Trust entry naming Epstein in a trustee or care-of capacity. The review says Leslie Wexner established and funded the charitable-remainder trust under a July 30, 1991 agreement and directed its charitable remainder to the Foundation.

Limits: The report recounts its review of the trust deed; the underlying deed and IRS return are needed for independent instrument-level authentication. Naming the trustee is not evidence that Epstein donated the underlying assets or routed narcotics proceeds.

Verify: Reconcile the 1991 instrument, 2001 Form 990-PF contribution schedule and custodian transfer confirmation; use distinct donor, trustee, recipient and beneficiary fields.

January 2008 transfer to YLK must stay separate from Wexner Foundation gifts

Documented: The review reproduces YLK reporting of $12,377,844 in assets from C.O.U.Q. and $34,280,154 in Apple shares from Financial Trust Company, totaling $46,657,998 in book-value receipts. YLK is a separate legal entity; it later wound down and transferred remaining assets to Wexner Family Charitable Fund.

Limits: The Wexners’ characterization of the 2008 transfers as partial restitution is an attributed claim. A previous Living Library filing reconciliation found differing donor and recipient values for the C.O.U.Q. noncash interests; the two numbers cannot be treated as identical independent cash payments. No connection to drugs is demonstrated.

Verify: Compare original noncash asset schedules, valuation dates, corporate resolutions and brokerage confirmations before assigning an economic source or purpose; keep 2001 Arts Trust out of this 2008 subtotal.

An August 2019 FBI tip about foundation money was logged as information only

Documented: An FBI FD-71A import record dated August 28, 2019 summarizes a third-party email alleging that Epstein gave roughly $9 million to the Wexner Foundation and referring to separate foreign payments. The associated incident summary lists information-only closure on August 28, 2019.

Limits: The assertions were a tip, not an FBI verification of payments. The similarly sized $9,588,560 Arts Interests Trust receipt may be relevant to follow-up, but equivalence cannot be assumed; neither record identifies a narcotics transfer.

Verify: Review the original tip enclosure only through authorized public release, obtain the original 2001 trust documents and payment vouchers for any claimed foreign recipient. Do not reproduce third-party contact information.

Rabbi Herbert A. Friedman: distinct Heritage Foundation cofounder

Documented: The review says Rabbi Friedman co-founded the separate Wexner Heritage Foundation with Leslie Wexner in 1985. The Heritage entity merged with the Wexner Foundation in 2005. The official Foundation biography records a historical executive leadership role.

Limits: Cofounding an entity years before Epstein became a Wexner Foundation trustee does not establish interaction with Epstein or criminal activity. No controlled-substance record appears in the sources.

Verify: Keep premerger corporate and grant authority separate and inspect historical signed records only when they directly bear on a defined research question.

Rabbi B. Elka Abrahamson: testimony-like interview account in counsel review

Documented: The review lists Abrahamson as a Foundation employee during part of Epstein’s trustee period, Vice President beginning 2005 and President from 2011. It attributes to her an interview statement that she never met Epstein and that he took no part in running the programs.

Limits: Interview recollections and institutional reports are evidence of what witnesses reported, not exhaustive archival proof of never having contact. Neither source connects Abrahamson to drug procurement or DEA Chain Reaction.

Verify: Reconcile staff tenure and signed governance or program records if a specific direct-contact claim arises.

Cindy Chazan: program-administration dates, distinct from financial signatory authority

Documented: The review lists Chazan as a Wexner Foundation employee from 1999 to 2017, Vice President during 2011–2016 and Senior Advisor during 2016–2017. She was interviewed for the February 2020 institutional review.

Limits: That record establishes organizational participation and the fact of an interview, not knowledge of Epstein’s unrelated activities, personal financial control, or any narcotics link.

Verify: Do not infer transaction authorization from executive program titles; consult dated board delegations and payment ledgers if direct transactions are alleged.

Rabbi Shoshana Gelfand: Heritage leadership during a separate corporate period

Documented: The review identifies Gelfand as a member of the first Graduate Fellowship class and an official of the separate Wexner Heritage Foundation during 1996–2004, including Vice President and Acting Director. It records that the researchers interviewed her.

Limits: Her employment and interview do not show contact with Epstein, funding of his activities, or involvement with narcotics. The Heritage corporate structure was separate until the 2005 merger.

Verify: Maintain correct employing organization and fiscal dates before attempting a grant or governance crosswalk.

Gideon Kaufman: Foundation trustee from 2007 and 2020 interviewee

Documented: The law firm lists Kaufman as a Wexner Foundation trustee beginning in 2007 and among people interviewed about Epstein’s historical role. The report separately dates Epstein’s own resignation as September 4, 2007.

Limits: The record does not establish the exact start date of Kaufman’s trustee service within 2007 or any meeting with Epstein; institutional overlap must not be presumed. No narcotics-related evidence was recovered.

Verify: Obtain dated appointment resolutions and minutes if a particular overlap or transaction requires testing.

Elizabeth Johnson is listed in Treasury disclosure scope without transaction proof

Documented: An introduced federal bill names Elizabeth Johnson among the individuals and entities in an Epstein-related Treasury records production proposal. That name appears near Johnson & Johnson, but the legislative list alone does not identify personal employment, a specific transaction or conduct.

Limits: The identity of this entry remains unresolved. Congressional inclusion is not a finding that an individual committed misconduct, had a narcotics link or appears in a produced SAR.

Verify: Establish exact identity and underlying cited source before any further individual attribution. Keep Johnson & Johnson separately classified as a corporate name.

Malcolm Grumbridge: FBI research concerned possible Maxwell defense witnesses

Documented: A publicly released FBI New York tactical intelligence report was prepared to screen potential defense witnesses in the Maxwell trial. It summarizes reported Maxwell-family professional associations and references an unrelated UK solicitor disciplinary matter. Separately, S. 2746 includes his name within a broad proposed SAR disclosure list.

Limits: An intelligence background report on prospective witnesses is not an accusation of participating in Maxwell’s offenses, and the disciplinary summary does not establish a narcotics offense. Neither source ties him to DEA Chain Reaction or an identified illicit pharmaceutical transfer.

Verify: Verify original UK regulator final decision and any actual transaction instruments before drawing a relationship or banking conclusion. Omit personal travel identifiers and any private source data.

Apgar Ambulances: two payments totaling $43,634

Documented: A bank-prepared presentation to federal prosecutors identifies two payments totaling $43,634 to Apgar Ambulances, through First Interstate Bank of Bozeman, from LSJE, LLC. The bank describes purchase of a 2009 Dodge 3500 XLT Wheeled Coach ambulance in late 2015 or early 2016.

Limits: The bank’s transaction classification establishes the described purchase and reporting amount only. It provides no evidence of a controlled-substance transaction, ambulance use, or joint operation with DEA Chain Reaction.

Verify: Seek the sales invoice, title-transfer documents and supporting wire details if publicly available. Keep this vehicle apart from aircraft and narcotics claims.

Concierge physician: five $25,000 payments totaling $125,000

Documented: The bank listed five payments to Bernard M. Kruger, MD: one three-payment group totaling $75,000 and two additional $25,000 payments. The bank noted that four payments were checks and that its single identified wire was described as Priority Private Care for Epstein and five assistants.

Limits: A physician’s receipt of reported payments and an office-service description do not establish medical treatment, access to prescriptions for others, criminal wrongdoing or purchases of illicit drugs. The document quotes a separate civil allegation without adjudicating it.

Verify: Obtain payment instruments and service agreements lawfully, retain aggregate and channel distinctions, and exclude patients’ identifying details.

CPR training: three payments totaling $1,317

Documented: Deutsche Bank identified two CPR123, Inc. payments aggregating $667 from an Epstein personal account and a $650 payment from NES, LLC, for three payments totaling $1,317. The bank said the payments were flagged because of the earlier ambulance purchase.

Limits: The bank’s explanation identifies a compliance review rationale, not an inference that an ambulance had been used or that narcotics were involved.

Verify: Reconcile invoice descriptions and dates if they become public; do not add the $1,317 to the ambulance vendor payment because the beneficiaries differ.

Identity warning: medical-sounding recipient cannot be equated with unrelated convicted doctor

Documented: A bank table names a payment recipient and groups 12 transactions into $43,863, $6,626 and $5,000 amounts, totaling $55,489. Bank analysts discussed an unrelated Florida doctor of a similar name convicted in a painkiller-related manslaughter case, expressly saying they could not confirm a match and citing possible travel restrictions inconsistent with one transaction narrative.

Limits: The payment recipient must not be identified as the convicted physician from a name match. The table establishes no opioid purchase, narcotics distribution, or trafficking link. Linking these identities would create an unsupported accusation.

Verify: Request authenticated beneficiary identifiers and transaction instructions lawfully, with personally identifying information withheld from public presentation. Treat the homonym as unresolved.

Doug Band: aircraft witness interview separates firsthand travel observations from earlier reporting

Documented: Band testified that he had traveled on Epstein’s aircraft while staffing President Clinton, describing where passengers and Epstein sat. He stated that he did not recall personally engaging with Epstein during the flights and described uncertainty over how his earlier media statements about advising Clinton to distance himself were phrased.

Limits: The interview is evidence of Band’s testimony, not a finding about the conduct of others. It provides no identified narcotics supply, financial drug transfer or DEA Chain Reaction connection.

Verify: Compare specific transcript answers with contemporaneous flight manifests and dated public statements before interpreting a remembered conversation.

Ted Waitt: personal association and 2003 dinner are independently dated by testimony

Documented: Waitt testified that he met Ghislaine Maxwell at a November 2003 dinner to which Doug Band invited him. He later confirmed Maxwell accompanied him to Chelsea Clinton’s July 2010 wedding while they were dating. His testimony also distinguished what he personally witnessed from events about which he was uncertain.

Limits: A historical intimate relationship, attendance at a public wedding and recollections of meetings do not establish involvement in Epstein’s offenses or in narcotics and pharmacy activity.

Verify: Maintain explicit witness attribution and event dates, and search additional primary records only where a particular allegation calls for them.

Charles J. Kegler: coauthor of the Foundation-commissioned historical review

Documented: Kegler is listed on the signed-identification cover of a legal review commissioned by the Wexner Foundation. The report describes its remit as investigating Epstein’s involvement with the Foundation, including the trusteeship and financial record review, using interviews and tax and trust records.

Limits: The document records Kegler’s role as outside counsel preparing an institutional review. Its assertions are the reviewed institution’s commissioned findings and should be independently checked against original instruments where possible. Nothing in this role suggests narcotics involvement.

Verify: Reconcile underlying trust agreements and Form 990-PF returns and preserve the distinction between commissioned conclusions and independently established bank transfers.

Loriann E. Fuhrer: coauthor of the February 2020 Foundation review

Documented: Fuhrer is named with Charles J. Kegler as a legal author of the Wexner Foundation-commissioned report. It describes searches of foundation corporate, tax, trust and interview materials concerning Epstein’s role and the attribution of transfers.

Limits: Coauthoring an institutional review is not evidence of involvement in the financial instruments under review. The report does not link Fuhrer to controlled substances, DEA operations or illicit transfers.

Verify: Preserve report-authorship provenance and obtain original agreements or bank documentation before strengthening any financial conclusion.

Morosky’s 2019 FBI call documented a report concerning 1990s aircraft

Documented: An FBI crisis-intake page records Morosky volunteering information about alleged use of Limited-branded aircraft to transport young girls from Mexico to the United States during the 1990s. The page documents his contact with investigators and his description of a professional relationship with Wexner.

Limits: The intake does not authenticate a manifest, passenger identity, date or aircraft tail number. It does not show an interview follow-up or establish that the reported movements occurred. It contains no identified controlled substance, drug shipment, DEA Chain Reaction target assignment or financial narcotics nexus.

Verify: Seek an authorized FBI follow-up interview, contemporaneous flight logs, customs entries and chain-of-custody records. Keep the FBI’s reception of a lead separate from subsequent proof; omit private contact information.

Zinoviev’s 2009 sworn affidavit establishes employment and a specific event

Documented: Zinoviev stated under oath that he worked for Epstein and drove him. The affidavit describes where he parked and how Epstein departed a building during an identified event.

Limits: This is Zinoviev’s sworn account in an adversarial civil proceeding. It supplies no pharmacy order, controlled substance, administration of drugs to a person, verified aircraft travel or criminal finding against the witness.

Verify: Consult the preceding motion, exhibits and any judicial findings for the narrow dispute addressed by the affidavit. Preserve the filing’s original context and avoid importing separate allegations into these paragraphs.

Fedus-Fields and the reported 1993 model-scout warning

Documented: The June 2021 Vanity Fair investigation reported that Fedus-Fields, then the catalog executive, was told in 1993 of a warning concerning Epstein’s representation that he recruited Victoria’s Secret models. It also published her recollection of personally declining inappropriate invitations. The account of a message reaching Wexner was attributed to another source briefed on the exchange.

Limits: The article is a journalistic account rather than a recovered 1993 internal warning, a sworn examination or a corporate finding. It supplies no allegation by Fedus-Fields of narcotics acquisition or administration and does not show that she committed misconduct.

Verify: Seek a lawfully released contemporaneous employee complaint, follow-up memorandum or original interview recording before upgrading the historical notification chain. Do not infer drug involvement from model-scout allegations.

Bannon messages on iPhone described as outside one search warrant

Documented: A federal prosecutor informed a colleague on April 12, 2021 that a number of Bannon–Epstein text messages were on an iPhone 7 and were outside the scope of that warrant. A separate DOJ-released March 2018 correspondence chain records discussions about a dinner and political news.

Limits: The message does not reproduce the texts or say they were examined for narcotics; the particular warrant scope cannot be generalized to other investigations. Neither document identifies drug transport, prescribing, funds tied to DEA Chain Reaction, or an illegal transaction.

Verify: Seek a lawfully released warrant inventory and the operative scope language before characterizing the nonresponsive classification. Preserve distinction between evidence collection and substantiated conduct.

Brockman correspondence discusses privately funded scientific meetings

Documented: In an August 2009 correspondence chain Epstein said he intended to fully fund gatherings on science topics; Brockman cautioned that involving the Templeton organization could affect participation. In an August 2013 chain Brockman sought Epstein’s input on a farm meeting.

Limits: An invitation or funding proposal does not establish payment, completed sponsorship, participants’ wrongdoing or a narcotics link. Names in forwarded messages must not be assigned an unwarranted financial role.

Verify: Seek contemporaneous invoices, contracts or receipts for a narrowly defined event, if lawfully public; do not infer spending totals from announcements.

ASU foundation acknowledgment: Enhanced Education check versus named foundation

Documented: Krauss told Epstein that a check came into the ASU Foundation from Enhanced Education, differing from the Florida Science Foundation name Krauss expected to acknowledge. Epstein answered with the name Jeffrey Epstein Foundation. This is an identifiable correspondence-level source-of-funds and acknowledgment discrepancy.

Limits: The amount, date of bank settlement, signed donor agreement, clearing check, and public gift ledger have not been verified. It would be incorrect to treat all three organization names as identical legal entities or to classify a science gift as drug proceeds.

Verify: Check lawfully public ASU Foundation gift acknowledgment and IRS 990 disclosures for legal entity names, exact amount, dates and any reversal; retain the original email without revealing personal contact details.

Michael Wolff advised on potential coverage of settlement disputes

Documented: The December 2018 email shows Wolff responding to Epstein’s request for an assessment of potential press attention concerning his assertions about a legal settlement and its proceeds. Wolff suggested looking to a journalist and a particular newspaper.

Limits: The email does not establish that the assertions about settlement beneficiaries were true, that Wolff controlled litigation or money, or any drug procurement or money-laundering nexus.

Verify: Compare contemporaneous filed settlement documents before describing actual disposition of funds. This email alone should remain a media-contact classification.

Chopra exchange proposes agency-administered science challenge

Documented: Emails discuss a proposed challenge concerning methods of studying consciousness. Epstein offered to fund prizes while Chopra suggested a separate organization should issue the challenge and discussed anonymity of Epstein’s role.

Limits: No grant contract, actual donation, prize recipient or bank transfer is established in this chain. It has no identified connection to controlled substances, clinical treatment, drug-facilitated abuse, or DEA Chain Reaction.

Verify: Check public charity filings and contemporaneous program announcements for whether the proposal occurred, without treating a proposed financial amount as paid.

Sergey Brin referral claim: the bank disputed its source while acknowledging other records

Documented: The USVI asserted that Epstein referred Sergey Brin to JPMorgan, citing testimony of banker Jes Staley. JPMorgan specifically disputed that referral conclusion. The parties identified a 2004 JPMorgan Private Bank client relationship, a Staley-to-bank-officer referral, and a 2006 internal JPMorgan email describing Epstein as an adviser to the Google founders. The bank accepted that the 2006 email contained the words quoted in the court filing. A July 2014 description of the overall Brin Private Bank relationship as exceeding $4 billion is a relationship-size description, not a payment to Epstein.

Limits: The USVI statement is a litigant contention where contested; the 2006 email reflects what a bank employee wrote, without establishing an actual adviser engagement or wrongdoing by Brin. No drug transaction, Epstein-linked proceeds, Chain Reaction participation, or personal knowledge of abuse is demonstrated.

Verify: Trace deposition Exhibit 46, internal Exhibit 190 and the full bank response to the exact referral and adviser propositions. Do not add relationship assets to Epstein cash flows or equate Brin with other Google individuals.

Brad Karp gave Epstein comments on a proposed court motion challenging survivors’ position

Documented: A released March 3, 2019 email identifies Karp as responding directly to Epstein with praise for a draft motion opposing efforts to challenge the earlier federal non-prosecution agreement. The correspondence contains Karp’s unfavorable characterization of survivors’ timing in bringing their claims. Epstein forwarded that correspondence to other lawyers involved in his defense discussion. This is evidence of a communicated litigation position and recipient network.

Limits: The communication does not establish which advice was adopted by the court, whether Karp controlled any client funds, or narcotics activity. Any other billing-allocation correspondence requires its own instrument-level verification before being treated as a paid professional fee.

Verify: Compare the exact EFTA pages with the filed motion and docket disposition. Do not import counsel rhetoric as an adjudicated finding about survivors and do not infer an illicit payment from legal representation.

Peter Attia: released correspondence proposes a medical evaluation

Documented: A released dated email from a physician to Epstein’s administrative staff proposes arranging an in-person evaluation. Only the existence and scheduling purpose of the correspondence is used here; patient-specific details are excluded from this Atlas.

Limits: A proposed evaluation does not prove that an appointment occurred, that a prescription was written, or that any medicine or controlled substance was supplied. No DEA Chain Reaction connection is identified. The source includes a patient-confidentiality warning; republishing clinical details would be unnecessary.

Verify: Limit any future pharmacy inquiry to lawfully releasable, appropriately redacted instruments that directly establish a relevant purchase or controlled-substance diversion. Preserve medical privacy.

James S. Crown appeared on JPMorgan’s 2017 director-election slate

Documented: A JPMorgan filing with the SEC for its May 16, 2017 annual shareholder meeting lists James S. Crown among the nominees for the board of directors. This is a dated corporate governance reference within the period when the bank’s prior Epstein relationship has been examined through separate litigation.

Limits: A director slate identifies an institutional role; it does not identify any specific account review, suspicious-activity decision, fund transfer, or involvement in DEA Chain Reaction by Crown. The record does not establish which committees reviewed Epstein.

Verify: Consult proxy committee memberships and original dated board minutes, if lawfully published, before asserting any personal decision on compliance or client retention.

Sharen Turney: distinguish Victoria’s Secret Direct from later overall brand leadership

Documented: In the company’s 2004 investor update Turney described herself as president and chief executive of Victoria’s Secret Direct while introducing Grace Nichols as president and chief executive of Victoria’s Secret Stores. The 2016 10-K says Turney had led Victoria’s Secret overall since July 2006 and that the company announced her resignation on February 12, 2016, after which Wexner assumed leadership.

Limits: The two corporate records establish changes in formally reported responsibilities. They do not establish personal involvement in Epstein’s activities or show any narcotics or pharmaceutical transaction.

Verify: Separate Direct, Stores and corporate-level decision rights by date before attributing any particular model-scout warning or operational decision.

Grace Nichols: Victoria’s Secret Stores role documented separately from Direct

Documented: The company-filed October 2004 transcript explicitly identifies Grace Nichols as the president and chief executive of Victoria’s Secret Stores. Sharen Turney’s statement distinguishes Nichols’s Stores responsibilities from Turney’s then Direct-channel role. A speaker heading elsewhere in the transcript uses an inconsistent role caption, making the first-person organizational introduction the better narrowly attributed source.

Limits: An executive title supplies historical responsibility boundaries but does not prove receipt of any report about Epstein, knowledge of abuse, a drug-related payment or a DEA connection.

Verify: Locate dated internal model-scout warning records, reporting lines and contemporaneous company responses rather than assigning responsibility from a title alone.

Couturier interview records contractor account and conflicting administrative dates

Documented: A published FBI interview record attributes to Couturier a 2010 Little Saint James design commission and an account of an Epstein flight to the island. Couturier told the FBI he received a $50,000 deposit and later ended the work after becoming uncomfortable with the proposed environment. The document header shows approval and serialization on November 16, 2010, while the body dates the interview to November 17, 2010.

Limits: This is a recorded witness account, not flight-manifest corroboration or proof of any narcotics activity. The administrative date conflict is unresolved. Do not identify individuals concealed by redactions.

Verify: Obtain the original FD-302 creation and amendment audit trail, the retained 2010 flight manifest and dated project agreement; distinguish interviews conducted from documents approved.

Little Saint James contractor invoice identifies a distinct partial payment

Documented: An April 30, 2010 invoice from Robert Couturier, Inc. bills $26,800 for architectural work, shows $12,500 in payments applied and states $14,300 still due. The invoice refers to the Little Saint James project.

Limits: The $12,500 applied amount cannot be presumed to be identical to or a subset of the separate $50,000 deposit described in the later FBI interview without check-level reconciliation. Neither entry is evidence of narcotics financing.

Verify: Identify the check numbers, paid-invoice ledger and credit memos, and reconcile dates and scope with the later retainer dispute.

Couturier retainer correspondence contradicts a simple net-payment reconstruction

Documented: Epstein lawyer Darren Indyke wrote to Couturier company counsel that the contract treated $25,000 of a $50,000 retainer as development compensation and the remaining $25,000 as prospective fee credits. His July 29 letter proposed refunding $50,000 minus $6,324.59 of asserted travel expenses. Couturier later told the FBI that he returned $15,000. These are distinct dated accounts and negotiating positions.

Limits: A proposed compromise and a witness account of eventual settlement do not establish the amount ultimately cleared. Neither proves illegality or narcotics use.

Verify: Seek the executed resolution, bank debits, invoices and receipts to reconcile the proposed refund, claimed expenses and reported $15,000 repayment.

NYSG shipping register connects Lauren Wintner and Julie Ferree by a dated delivery

Documented: A February 23, 2001 FedEx invoice billed to NYSG LLC lists a February 13 pickup from a sender rendered in the carrier record as Lauren Kwinther and delivery to Julie Ferree at The Limited, on February 14. The names and destination appear in the carrier transaction record and identify administrative routing between offices.

Limits: The sender is OCR-rendered as Kwinther in this source, so full-name normalization to Lauren K. Wintner remains provisional until confirmed against matching shipping records. The envelope contents, institutional purpose and each recipient’s knowledge are absent. A shipment provides no narcotics indication.

Verify: Cross-match original paper shipping labels, sender employment history, account charges and package descriptions. Do not infer contents or financial instruments from a carrier bill.

March 2001 shipment lists Karl Heinz Schwabe as both sender and recipient

Documented: A March 16, 2001 FedEx invoice billed to NYSG LLC includes an overnight delivery on March 9 to Karl Heinz Schwabe in Dayton, Ohio, with the same name in the shipper field and NYSG’s Manhattan address. Separate rows in that invoice identify deliveries involving Lauren Kwinther and Peg Ugland. The document establishes the carrier’s billing and routing entries only.

Limits: The record does not explain whether the sender field identifies the individual preparing the package or a billing convention. It contains no package inventory, pharmacy reference, evidence of drugs or knowledge of criminal conduct.

Verify: Check original carrier labels and billing authorization against NYSG employment and delivery records. Keep possible spelling variations separate until matched.

Isabel Goldsmith is named in Couturier’s introduction account

Documented: The FBI record says Couturier first met Epstein sometime during 1985–1988 through a woman spelled Ysabel Goldsmith. Journalist Edward Jay Epstein described attending a 1987 gathering with Isabel Goldsmith at which he met Jeffrey and Mark Epstein. The two accounts independently place a Goldsmith-named acquaintance in Epstein’s social milieu during the late 1980s.

Limits: The FBI spelling differs from the matrix spelling. The accounts do not demonstrate any financial control, drug procurement, trafficking or criminal participation by Isabel Goldsmith. A social introduction must not be treated as a criminal connection.

Verify: Seek Couturier’s original signed witness notes, historical invitation records and any identification clarifying the Ysabel/Isabel spelling without publishing private contact details.

Couturier attributed a late-1980s warning about Epstein to Sir James Goldsmith

Documented: In a reported October 2026 interview, Couturier said Sir James Goldsmith had warned him around 1987 about Epstein’s behavior toward minors and urged him to avoid Epstein. The Guardian reported that Goldsmith’s daughter Jemima separately said she had heard her father disliked Epstein. This is attributable testimony about a historical warning, not a contemporaneous memorandum.

Limits: Goldsmith died in 1997 and cannot confirm the recollection. The Guardian reported no evidence he made a law-enforcement complaint or that he participated in narcotics transactions. Do not collapse a personal warning into knowledge of any specific later offense.

Verify: Seek independently dated correspondence or contemporary corroborating testimony, and distinguish personal warning, firsthand observation and later interpretation.

Three successive chefs identified in a 2006 FBI interview

EXP-039 Lance Calloway; EXP-040 David Mullen; EXP-041 Brent Tindall | EFTA00269585–587 | David Rogers interview 2006-08-18

Documented: A released FBI record of David Rogers’s August 18, 2006 interview lists Lance Calloway as Epstein’s chef for the preceding year, David Mullen as his predecessor, and Brent Tindall as a chef in 2004. The record identifies the information as Rogers’s recollection and contact list; it does not supply employment contracts, invoices or duty logs.

Limits: None of these three names is thereby implicated in drug-facilitated abuse or narcotics supply. The same 2006 interview also appears under a later electronic-communication entry (EFTA00269580–582); the copies must be treated as one witness account, not independent corroborations.

Verify: Reconcile staff employment dates against individual interviews and independently dated payroll or work records. Do not publish private phone numbers contained in FBI contact lists.

Calloway separately described his employment to federal investigators in 2021

EXP-039 Lance Calloway | FBI FD-302, 2021-02-03 | EFTA00083812

Documented: The published first page of an FBI FD-302 says Lance Calloway reported being employed by Epstein from approximately winter 2006 until January or February 2009 after being interviewed for a chef position. The source describes an interview with investigators, not a court finding.

Limits: The interview-derived starting date is not a precise match for Rogers’s August 2006 reference to Calloway as chef for the prior year. The accessible extraction here is incomplete and its third-party index reports a hash warning; no firm chronology, food tampering or drugging claim can be inferred from the partial transcription.

Verify: Inspect all four original DOJ-scanned pages and compare dates with contemporaneous job records. Retain the source-integrity flag until scan and checksum are independently reconciled.

Mike Sitrick coordinated suggested public messaging after the conviction

EXP-009 Mike Sitrick | EFTA00702839–841 | emails March 15, 2011

Documented: Released March 15, 2011 emails show public-relations adviser Mike Sitrick corresponding with Epstein and lawyer Paul Tweed about proposed wording rebutting press reporting. The thread contains edits requested by Epstein and draft language defending him; this supports a specific reputation-management role in a dated exchange.

Limits: Draft wording is not a judicial finding, the accuracy of its assertions must not be adopted, and the correspondence does not demonstrate drug procurement, banking transfers or participation in abuse.

Verify: Match the circulated draft to any published statement, retainer agreement or invoice before claiming distribution or compensation. Preserve the full context of the 2011 conviction-related record.

Rabbi Jay Henry Moses: Foundation employment began in 2003

EXP2-037 Rabbi Jay Henry Moses | Wexner Foundation biography, undated current-page record

Documented: The Foundation’s official biography says Jay Henry Moses joined its staff in 2003 and later became a vice president, with responsibilities connected to the Heritage Program. The 2003 start date overlaps the final years of Epstein’s formally documented Foundation trusteeship, without showing any personal contact.

Limits: This biography describes ordinary professional activity. It establishes no drug transaction, procurement decision, personal contact with Epstein or oversight of his separate finances. Do not confuse Jay Henry Moses with Larry S. Moses, whose Foundation presidency is documented separately.

Verify: Search contemporaneous board minutes and dated correspondence only if an identifiable Foundation decision intersects the relevant investigations.

Or Mars: professional leadership position in a Foundation program

EXP2-038 Or Mars | Wexner Foundation official biography

Documented: The Foundation’s official biography identifies Or Mars as a vice president focusing on professional and volunteer leadership programs and states he joined the staff in 2006. This is a biographical employment fact; the web biography is not evidence of his position or duties in every earlier year.

Limits: The time overlap with Epstein’s trusteeship does not demonstrate that Mars met Epstein, knew of abuse, signed transactions or participated in drug-related activity. Similar names in IRS returns require independent identity reconciliation before aggregation.

Verify: Identify dated role descriptions, board approvals or contracts if a substantive relationship emerges. No narcotics nexus was established by the scoped source review.

Ra’anan Avital: 2017 Jerusalem appointment follows Epstein’s trustee tenure

EXP2-039 Ra’anan Avital | Wexner Foundation announcement, April 24, 2017

Documented: The Foundation’s April 24, 2017 announcement reports that Ra’anan Avital had become director general of its Jerusalem office earlier that month. The announcement describes a leadership recruitment process and a conversation with Leslie and Abigail Wexner about the program.

Limits: The appointment occurred approximately ten years after the Foundation says Epstein resigned as a trustee in September 2007. The announcement does not establish personal contact with Epstein, illicit transfer authority, pharmaceutical supply or narcotics activity.

Verify: Preserve the 2017 start date and distinguish Foundation program roles from the separate financial entities examined in the Atlas.

Stefanie Zelkind: 2016 staff appointment is chronologically distinct

EXP2-040 Stefanie Zelkind | Wexner Foundation official biography

Documented: The Foundation’s biography states Zelkind joined its staff in 2016 and later held leadership roles related to the Graduate Fellowship and professional-leadership alumni networks. The posting describes program management rather than financial custody.

Limits: Because her staff tenure began after Epstein’s 2007 resignation, employment alone supplies no contemporaneous trustee-period connection. No documentary drug, pharmacy or DEA nexus is identified in this source.

Verify: Keep staff-start dates separate from alumni status and avoid treating institutional membership as proof of knowledge about Epstein.

Ed Razek: 2018 interview documents fashion-show marketing role

EXP2-027 Edward “Ed” Razek | Vogue, interview with Nicole Phelps, November 8, 2018

Documented: A November 8, 2018 contemporaneous interview identifies Razek as chief marketing officer of L Brands and quotes him on Victoria’s Secret fashion-show strategy and model selection culture. The interview confirms the existence of his statements and professional remit as described by the publication.

Limits: The interview contains no narcotics evidence and does not independently resolve whether Epstein used the company’s name to mislead prospective models. A marketing role alone is not proof of knowledge of any specific abuse.

Verify: Use separate primary witness statements, contemporaneous policies and documented communication where particular modeling-recruitment claims require examination.

Monica Mitro: 2018 interview records Victoria’s Secret public-relations duties

EXP2-028 Monica Mitro | Vogue, November 8, 2018 interview

Documented: The same dated interview identifies Mitro as Victoria’s Secret’s executive vice president of public relations and records her own account of work around the 2018 runway production, model public messaging and coordination of fashion-show assets.

Limits: Her professional role and interview statements provide no documentary evidence that she participated in any Epstein operation, drug purchases or drug-facilitated abuse. Her remit must not be merged with Razek’s separate marketing role.

Verify: Seek issue-specific letters and signed approvals if any event calls for an attribution beyond the published interview.

Foundation accounting was serviced through N.A. Property, with a material records gap

Wexner Foundation commissioned report, February 24, 2020, pp. 2–3, 5, 11–12

Documented: Reviewing lawyers reported that the Foundation’s payroll, ledger, banking and Form 990-PF preparation were handled by N.A. Property, a separate Wexner family financial office. Their review says Epstein, despite holding a senior title in that family office, was not found personally to have carried out these accounting tasks. The reviewers relied on interviews and records, and explicitly said the Foundation’s email archive did not extend back into Epstein’s trustee years.

Limits: The report is commissioned by the organization being reviewed, and its findings should be attributed rather than treated as an adjudication. Absence of historical emails limits its ability to establish informal contacts or a complete approval chain. No DEA-linked bank transfer or narcotics proceeds are identified by this report.

Verify: Request contemporaneous general ledgers, signed trust/board resolutions and accounting engagement letters if lawfully public, crosswalking Foundation, Heritage, YLK and N.A. Property as separate entities.

Wexner’s 2026 lack of recollection does not itself invalidate the 2020 interview list

Wexner Foundation report (2020) pp. 3–4; House Oversight deposition February 18, 2026, approximately 1h22m

Documented: The 2020 commissioned Foundation report lists Leslie Wexner among those interviewed. When shown the report during his February 18, 2026 congressional deposition, Wexner said he had no recollection of that report or being interviewed, while also indicating he had no basis to dispute the report’s statement. The committee later released the deposition video.

Limits: The two records establish an inconsistent degree of recollection, not proof of a false statement or misconduct. The available time-coded transcript is a third-party transcription and is subordinate to the original committee-released video. Neither record identifies narcotics transactions.

Verify: Obtain the original interview memorandum and any committee-certified deposition transcript if publicly released. Preserve counsel questions and surrounding answers in the comparison.

Douglas Leese: distinguish 1996 parliamentary allegation from Epstein correspondence

EXP-007 Douglas Leese | Commons Hansard, 24 Jan 1996; EFTA00663868, 16 May 2009

Documented: In a 24 January 1996 parliamentary debate George Galloway alleged Douglas Leese was involved in commissions on an arms arrangement with Saudi Arabia. A separate May 2009 email exchange between Epstein and Nick Leese concerns Douglas’s worsening health. These records establish a parliamentary accusation and correspondence in a different period.

Limits: Parliamentary privilege and publication do not adjudicate the arms commission allegations. The email does not establish completed financial transfers, drug-related transactions or a role in DEA Chain Reaction.

Verify: Obtain banking/contract records if lawfully released; do not merge allegations about arms commissions with Epstein-related narcotics intelligence.

Landon Thomas Jr.: reputation advice and a proposed banker introduction

EXP-014 Landon Thomas Jr. | EFTA00669361, 9 Jan 2015; EFTA01048812 and EFTA01048814, 21 Apr 2017

Documented: A 2015 email shows Thomas suggesting a public response to accusations concerning Epstein. In April 2017 correspondence Thomas asked whether a meeting with Nathan Myhrvold could be offered to bankers associated with Masa; Epstein replied about Myhrvold as a potential reference. The text documents discussions about an introduction.

Limits: No resulting introduction, account opening, payment or illicit financial transfer is established from those emails. The interactions are not evidence of narcotics purchases or trafficking by Thomas.

Verify: Identify any completed transaction only from authenticated bank or meeting documents; maintain dated correspondence and journalistic source boundaries.

James W. Schacht: insurance regulator brought 1991 Towers-related civil claims

EXP-043 James Schacht | Schacht v. Hoffenberg et al., N.D. Ill. No. 91 C 4024; EFTA00612518, pp. 1 and 11–13

Documented: The June 1991 federal complaint identifies James W. Schacht as Acting Director of Insurance of Illinois and plaintiff acting as conservator/liquidator for affected insurers. The pleading identifies Towers-related defendants and reports checks to Epstein or Epstein & Co.; Epstein is not named as a defendant in its caption.

Limits: The source is a civil pleading setting forth the regulator’s allegations, not a finding of liability or evidence that Schacht approved the transactions. It predates the 2010–2015 DEA case by decades and proves no narcotics relationship.

Verify: Seek the 1991 docket, authenticated check images, vouchers, deposition testimony and ultimate court disposition; do not attribute the allegations to Schacht personally.

Kenneth Lipper: distinguish Harvard Hillel 1991 fundraising pledge from an Epstein donation

EXP2-011 Kenneth Lipper | 1991 New York Times reporting as cited by Harvard Crimson; 2019 Harvard Hillel director response

Documented: Contemporaneous 1991 reporting identified Kenneth Lipper alongside Wexner, Epstein and Robert Meister as participants pledged to raise $2 million for the Harvard Hillel building. In 2019 Hillel director Steinberg told the Harvard Crimson that the organization’s records did not show a personal contribution from Epstein to the building project.

Limits: A multi-person fundraising pledge cannot be allocated to Lipper or Epstein as a completed transfer without receipts. This does not establish narcotics activity, and those philanthropic amounts must not be summed with DEA SAR totals.

Verify: Obtain the original 1991 pledge instruments, Hillel contributions register and individual donor receipts if available.

William Ebbing: New Albany Company presidency documented by the company

EXP2-020 William Ebbing | New Albany Company institutional publications, 2014

Documented: The New Albany Company’s own publications identify William Ebbing as its president and describe the company as a development business founded by Leslie Wexner and Jack Kessler. The material establishes his professional office and the corporate context for land-development decision-making.

Limits: Company leadership does not establish personal control of Epstein’s accounts, Wexner family foundation finances, controlled substances or any DEA Chain Reaction decisions.

Verify: Examine signed deeds, corporate minutes and authority instruments only where they bear directly on a documented financial or institutional question.

Sivan Shani: Israel program leadership postdates Epstein trusteeship

EXP2-041 Sivan Shani | Wexner Foundation official staff page and program page

Documented: The Foundation’s biography lists Sivan Shani as joining in 2019 and holding program-director responsibilities in Israel. Its program documentation independently lists responsibilities relating to leadership training.

Limits: The documented entry date is well after Epstein’s trusteeship and cannot supply evidence about his earlier financial authority. No narcotics procurement or related investigation connection was identified in these reviewed institutional documents.

Verify: Restrict further review to any dated formal decisions that actually intersect with the relevant investigation period.

Sharon Zini: 2017 entry and Israel program-coordination role

EXP2-042 Sharon Zini | Wexner Foundation staff biography and Senior Leaders program page

Documented: The Foundation biography dates Sharon Zini’s entry to 2017 and identifies her as a senior program coordinator working with Israeli programs. Its Senior Leaders page also lists her as program coordinator.

Limits: These role statements do not establish involvement in Epstein’s finances, procurement, DEA intelligence or controlled substances. The chronology follows the reported period of Epstein’s direct organizational involvement.

Verify: Preserve precise role dates and avoid expanding normal administrative responsibilities into personal accountability without specific original records.

Dara Katzner: 2016 staff entry and education-program remit

EXP2-043 Dara Katzner | Wexner Foundation personnel biography and Service Corps page

Documented: The Foundation states that Dara Katzner joined its staff in 2016 and identifies her role with the Field Fellowship and Service Corps educational programs. The public Service Corps page assigns her a program administrative contact function.

Limits: The record is limited to employment and program duties; it provides no evidence of involvement in the former Epstein trusteeship, financing or drug-facilitated abuse.

Verify: Keep employment chronology distinct from trusteeship periods; pursue additional source review only on a specific dated transaction or decision.

Dana Savoray-Hadar: 2014 Foundation entry with documented Israel program remit

EXP2-044 Dana Savoray-Hadar | Wexner Foundation official biography; Aug 2022 coauthored essay

Documented: The Foundation reports that Dana Savoray-Hadar joined in 2014 as deputy director of its Israel office. A 2022 article she coauthored identifies her work on alumni activities, allowing this record to attribute her program leadership to a specific later period.

Limits: These dated organizational records provide no evidence of a DEA-related transaction or knowledge of Epstein-era trust decisions. A present-day program title does not retroactively establish control over historical payments.

Verify: Reconcile any specific claimed approvals against contemporaneous signatory records; no personal narcotics claim is supported.

1991 Towers insurer complaint itemizes Epstein-payee checks totaling $215,000

Schacht v. Hoffenberg et al., N.D. Ill. 91 C 4024, EFTA00612518–EFTA00612531, allegations in complaint ¶¶38–43

Documented: The original filed complaint lists checks drawn on United Fire Insurance and United Diversified accounts during 1987–1988 with payee names Jeff Epstein and Jeffrey Epstein. Its paragraph 43 asserts that checks payable to Epstein or Epstein & Co. totaled $215,000. Other paragraphs allege that supporting vouchers were not supplied and that related funds were used for a failed investment in Emery Air Freight.

Limits: A complaint proves that a regulator made these allegations and printed an itemized schedule; it does not establish bank clearance, ultimate beneficial ownership, the merits of each alleged violation or adjudicated liability. The payments are decades earlier than DEA Chain Reaction and may not be aggregated with its seven SAR references.

Verify: Acquire the original 1987–1988 check images and negotiated instrument records, bank account statements, 1991 case outcome and any insurer liquidation ledger; avoid double-counting individual rows and pleaded total.

Sandy Lewis describes Wexner acquisition advice and later Epstein displacement

EXP2-010; William D. Cohan interviewing Salim B. Lewis, Vanity Fair, 8 August 2019

Documented: Lewis told Cohan he helped Wexner on the 1982 Lane Bryant acquisition, arranged credit for a proposed transaction, received a reported $750,000 professional fee, and became a limited-partnership investment recipient. He contrasted those earlier dealings with Epstein’s later role managing Wexner funds.

Limits: The dollar amount, payment date, completed credit arrangements and ultimate accounts are reported by Lewis or the journalist, not verified by primary bank instruments in this pass. Lewis’s interpretation of Epstein’s motives is opinion and does not establish misconduct by Lewis. No connection to the DEA narcotics file.

Verify: Find Wexner and Lewis contemporaneous engagement agreements, acquisition transaction documents, check images and partnership statements; distinguish advisory fees from later Epstein activity.

John Gardner McCoy: Banc One governance and New Albany philanthropy

EXP2-022; family obituary issued April 2010

Documented: The John Gardner McCoy memorial record identifies service at City National Bank and Banc One from 1937, leadership of the bank organization, and philanthropic ties to the Columbus area. It identifies John B. McCoy as his son.

Limits: An obituary is a family-supplied biographical source. Institutional roles and geographic proximity do not demonstrate personal Epstein-account control or participation in narcotics activity. The DEA memorandum names neither McCoy in the reviewed public redactions.

Verify: Seek authenticated relevant period bank director filings, account records or specific transaction instruments before assessing any Epstein-specific financial link.

John Bonnet McCoy: separate Banc One executive and corporate governance record

EXP2-023; 2000 industry account, 2006 SEC N-PX, 2010 family obituary

Documented: An April 2000 account discusses former Bank One chief executive John B. McCoy’s departure following First USA performance problems. A 2006 SEC-filed N-PX contains the name John B. McCoy in an AT&T director-election ballot; his father’s obituary separately identifies the father and son. These establish role-specific dated references.

Limits: The N-PX documents how a reporting investment fund voted in an AT&T director election; it is not an Epstein banking account or evidence of control over a particular transaction. John B. and John Gardner must not be conflated.

Verify: Obtain direct dated Banc One annual reports, relevant bank-beneficiary documents if publicly available and a documented specific Epstein account connection before drawing any nexus.

Richard Himmel: documented Limited Stores design commissions, no established narcotics link

EXP2-025; Interior Design 1985 Hall of Fame profile (published 2014); University of Chicago Magazine Winter 2022

Documented: The professional design profile identifies Richard Himmel’s commercial aircraft and retail design work and several installations for The Limited Stores. The university’s historical account independently documents his Chicago practice, commissions and design chronology. This source set identifies a professional context with a Wexner company.

Limits: These documents do not establish Epstein involvement, private conduct, narcotics procurement or drug-facilitated abuse. Allegations elsewhere cannot be converted into findings through professional association. The June 1990 House & Garden text has only been located in an archival index/snippet and is not being treated as a fully verified original page.

Verify: Obtain the underlying contracts, project dates and the original magazine pages before dating Wexner-specific work more closely.

Élie de Rothschild: Wexner names Epstein financial reference, independent call record absent

EXP2-033; Leslie H. Wexner written House statement, February 18, 2026, p.2; Rothschild family genealogy; INHA biography

Documented: Wexner’s signed written statement says Epstein offered an Elie de Rothschild reference; Wexner claims he spoke with Elie, who recommended Epstein. The Rothschild family archive identifies Élie Robert de Rothschild (1917–2007), and the French art-history institute independently dates his biography. These records narrow the personal referent and fix the historical period.

Limits: The 2026 statement is a retrospective account from Wexner, not a recording or contemporaneous reference letter from Élie. No particular financial service, payment, underlying bank instrument or narcotics offense has been independently substantiated. Do not collapse separate Rothschild branches or 2015 Southern Trust contracts into a 1980s referral.

Verify: Seek 1980s reference correspondence, authenticated client agreements or records of services without speculating about family members.

Two federal programs independently used the name “Operation Chain Reaction”

DEA/OCDETF NY-NYS-0829, EFTA00173953; House Homeland Security hearing, November 15, 2022, GPO CHRG-117hhrg50981

Documented: A 2022 Homeland Security congressional hearing names HSI’s Operation Chain Reaction as an initiative to identify counterfeit goods entering the U.S. government supply chain. The 2015 Epstein-related intelligence memorandum and Senator Wyden’s 2026 inquiry identify a distinct OCDETF/DEA operation NY-NYS-0829 investigating suspected narcotics/financial activity. The similar names are not evidence of a shared case.

Limits: Combining news hits by operation title without agency, case number and subject risks importing unrelated investigative data. The signed DEA case closure, original SAR attachments and final disposition remain unavailable in the reviewed primary release; a secondary website’s precise 2023 closure date is unverified here.

Verify: Require the NY-NYS-0829 control number and the 2015 EFTA memo when identifying relevant DEA records; filter out HSI counterfeit-supply-chain material. Obtain DEA closing instrument before assigning a disposition or explaining prosecutorial decisions.

Bank of America to Epstein: eighteen Black-funded wires have a six-year $169.8 million schedule

Documented: The report identifies eighteen large transfers from Leon Black-controlled Bank of America accounts to Epstein-controlled Financial Trust Company accounts at JPMorgan and Southern Trust Company accounts at Deutsche Bank. Its annual amounts are 2012 $5.5m, 2013 $50m, 2014 $70m, 2015 $30m, 2016 $6.3m and 2017 $8m, totaling $169.8m. The report also specifies $140m to Southern Trust at Deutsche Bank during 2013–15, whereas the table totals $150m across the broader set of Epstein recipients for those same years.

Limits: The $140m and $150m figures have different stated recipient scopes. Both reflect Senate staff descriptions of bank reports inspected in camera and are not an instrument-by-instrument public ledger. The same transfer can pass through multiple institutions, and there is no finding here of payment for narcotics.

Verify: Obtain redacted original payment instructions for the eighteen wires; list origin bank, receiving bank, Epstein legal recipient, value date, reference number, amount and source filing. Reconcile 2013–15 recipient allocations before calculating any joint SAR aggregate.

Two 2020 Bank of America SAR reports require cohort deduplication

Documented: The committee report says a February 7, 2020 Bank of America SAR flagged approximately $156m of Black-to-Epstein payments. An October 2020 filing then reported two previously missed wires, $5.5m from November 2012 and $8m from 2017. Those additional wires correspond to years already included in the report’s six-year $169.8m summary.

Limits: Adding the rounded $156m and two stated transfers yields approximately $169.5m, $0.3m below the report’s $169.8m annual total; this is a rounding/source-scope question, not proof of a hidden payment. The later SARs describe past transfers and must not be counted again as additional funds. SAR statements flag suspicion, not proof of money laundering or narcotics procurement.

Verify: Match both SAR filing dates, amendment and related-case references to the eighteen unique payment instruments; retrieve precise unrounded totals and reconcile any coverage gap. Keep 2020 report dates separate from 2012–17 transfer dates.

Hyperion Air Inc. wired documented aircraft-title and refurbishment amounts in 2012

Documented: A February 2012 JPMorgan Hyperion Air Inc. account statement lists a $100,000 February 14 wire to Insured Aircraft Title Service associated with a Bell 430 helicopter, serial number 49078. A separate May 22, 2012 statement lists $110,100 to the same aircraft-title intermediary for a referenced refurbishment deposit. The payments are discrete bank entries at different dates and must remain distinct from later aircraft ownership-transfer paperwork.

Limits: The statement descriptions identify an aircraft-related commercial purpose on the bank record. They do not establish completed performance, actual beneficial purchaser, passage of any illegal goods or a relationship to DEA Chain Reaction. Do not infer that the funds moved through narcotics channels merely because an aircraft appears in the DEA profile.

Verify: Reconcile title escrow and aircraft purchase agreements, payment confirmations, the Bell 430 serial record, 2012 bank debit instruments and the recipient’s allocation ledger without exposing account numbers.

The 2013 Bell 430 transfer separates Hyperion Air Inc. from Hyperion Air LLC

Documented: Released FAA papers for Bell 430 serial number 49078 include an August 2013 bill of sale showing Hyperion Air Inc. as seller and Hyperion Air LLC as purchaser. A September 2013 temporary-registration record identifies Hyperion Air LLC and registration N331JE. These records create dated ownership-identity anchors after the 2012 Hyperion Air Inc. aircraft-related bank payments.

Limits: Corporate spelling Inc. versus LLC is legally consequential. A registration transfer does not itself establish fair-market price, the actual transfer consideration, narcotics transport or shared control of all bank accounts. The public source is a large composite FAA file, so use individual Bates pages for final verification rather than loose name matching.

Verify: Compare complete FAA bill of sale, pre- and post-transfer ownership records, consideration documents, helicopter serial number and original bank counterparty records. Keep this aircraft separate from other Hyperion aircraft and commercial-flight crossings in the DEA intelligence product.

New York regulator found serious Deutsche Bank monitoring failures; transaction purposes remain undetermined

Documented: The New York Department of Financial Services found that Deutsche Bank opened Epstein-related accounts in 2013, classified the relationship as high risk and failed to scrutinize suspicious activity commensurate with the risks identified. The order describes scrutiny failures concerning transfers to or on behalf of young women and other individuals and cash withdrawals averaging more than $200,000 annually. Paragraph 57 expressly leaves the purpose of those payments and withdrawals for criminal authorities to determine. The administrative findings concern Deutsche Bank's compliance obligations.

Limits: The regulatory findings do not prove that any particular transfer was for controlled substances, connect a Deutsche Bank payment to a DEA Chain Reaction SAR, or establish the case's disposition. Do not add the regulator's described cash activity to SAR, annual-wire, or other report totals without identifying unique transactions. The regulator anonymized some counterparties; preserve those identifiers and do not infer names.

Verify: Compare the exact reporting periods and transactions with released bank statements and regulatory exhibits. Underlying SAR schedules and DEA closure records remain absent from the reviewed public material; keep those acquisition targets open without treating absence as exculpatory or inculpatory evidence.